ES2503742T3 - Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN - Google Patents

Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN Download PDF

Info

Publication number
ES2503742T3
ES2503742T3 ES10183538.7T ES10183538T ES2503742T3 ES 2503742 T3 ES2503742 T3 ES 2503742T3 ES 10183538 T ES10183538 T ES 10183538T ES 2503742 T3 ES2503742 T3 ES 2503742T3
Authority
ES
Spain
Prior art keywords
seq
mir
hsa
mmu
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10183538.7T
Other languages
English (en)
Inventor
David Brown
Lance Ford
Angie Cheng
Rich Jarvis
Mike Byrom
Dmitriy Ovcharenko
Eric Devroe
Kevin Kelnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asuragen Inc
Original Assignee
Asuragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2503742(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asuragen Inc filed Critical Asuragen Inc
Application granted granted Critical
Publication of ES2503742T3 publication Critical patent/ES2503742T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

Una molécula de ácido nucleico miARN sintético que comprende una secuencia con una identidad de secuencia de al menos el 80% con la secuencia del miR-101 maduro humano para su uso en la terapia de un cáncer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
E10183538
17-09-2014
entenderá como tal dependiendo del contexto. A menos de que se indique otra cosa, los miARN a los que se refiere la solicitud son secuencias humanas identificadas como mir-X o let-X, donde X es un número y/o una letra.
Tabla 1
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-1-2
SEC ID Nº 1 53-73
hsa-mir-1-1
SEC ID Nº 2 46-66
hsa-let-7a-1
SEC ID Nº 3 6-27
hsa-let-7a-2
SEC ID Nº 4 5-26
hsa-let-7a-3
SEC ID Nº 5 4-25
hsa-let-7b
SEC ID Nº 6 6-27
hsa-let-7c
SEC ID Nº 7 11-32
hsa-let-7d
SEC ID Nº 8 8-28
hsa-let-7e
SEC ID Nº 9 8-28
hsa-let-7f-1
SEC ID Nº 10 7-28
hsa-let-7f-2
SEC ID Nº 11 8-29
hsa-mir-7-1
SEC ID Nº 12 24-44
hsa-mir-7-2
SEC ID Nº 13 32-52
hsa-mir-7-3
SEC ID Nº 14 31-51
hsa-let-7g
SEC ID Nº 15 5-25
hsa-let-7i
SEC ID Nº 16 6-24
hsa-mir-9-1
SEC ID Nº 17 16-38 y/o 56-76
hsa-mir-9-2
SEC ID Nº 8 16-38 y/o 54-74
hsa-mir-9-3
SEC ID Nº 19 16-38 y/o 56-76
hsa-mir-10a
SEC ID Nº 20 22-44
hsa-mir-10b
SEC ID Nº 21 27-48
hsa-mir-15a
SEC ID Nº 22 14-35
hsa-mir-15b
SEC ID Nº 23 20-41
hsa-mir-16-1
SEC ID Nº 24 14-35
hsa-mir-16-2
SEC ID Nº 25 10-31
hsa-mir-17
SEC ID Nº 26 14-37 y/o 51-70
hsa-mir-18
SEC ID Nº 27 6-27
hsa-mir-19a
SEC ID Nº 28 49-71
hsa-mir-19b-1
SEC ID Nº 29 54-76
hsa-mir-19b-2
SEC ID Nº 30 62-84
hsa-mir-20
SEC ID Nº 31 8-29
hsa-mir-21
SEC ID Nº:32 8-29
hsa-mir-22
SEC ID Nº:33 53-74
hsa-mir-23a
SEC ID Nº 34 45-65
hsa-mir-23b
SEC ID Nº 35 58-80
hsa-mir-24-1
SEC ID Nº 36 6-28 y/o 44-65
hsa-mir-24-2
SEC ID Nº 37 50-71
hsa-mir-25
SEC ID Nº 38 52-73
hsa-mir-26a-1
SEC ID Nº 39 10-31
11
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-26b
SEC ID Nº 40 12-32
hsa-mir-26a-2
SEC ID Nº 41 14-35
hsa-mir-27a
SEC ID Nº 42 51-72
hsa-mir-27b
SEC ID Nº 43 61-80
hsa-mir-28
SEC ID Nº 44 14-35
hsa-mir-29a
SEC ID Nº 45 41-62
hsa-mir-29b-1
SEC ID Nº 46 51-70
hsa-mir-29b-2
SEC ID Nº 47 52-71
hsa-mir-29c
SEC ID Nº 48 54-75
hsa-mir-30a
SEC ID Nº 49 47-68
hsa-mir-30c-2
SEC ID Nº 50 7-29
hsa-mir-30d
SEC ID Nº 51 6-27
hsa-mir-30b
SEC ID Nº 52 17-37
hsa-mir-30c-1
SEC ID Nº 53 17-39
hsa-mir-30e
SEC ID Nº 54 2-21
hsa-mir-31
SEC ID Nº 55 9-29
hsa-mir-32
SEC ID Nº 56 6-26
hsa-mir-33
SEC ID Nº 57 6-24
hsa-mir-34a
SEC ID Nº 58 22-43
hsa-mir-34b
SEC ID Nº 59 14-35
hsa-mir-34c
SEC ID Nº 60 13-34
hsa-mir-92-1
SEC ID Nº 61 48-69
hsa-mir-92-2
SEC ID Nº 62 48-69
hsa-mir-93
SEC ID Nº 63 12-33
hsa-mir-95
SEC ID Nº 64 49-70
hsa-mir-96
SEC ID Nº 65 9-30
hsa-mir-98
SEC ID Nº 66 2-23
hsa-mir-99a
SEC ID Nº 67 13-34
hsa-mir-99b
SEC ID Nº 68 7-28
hsa-mir-100
SEC ID Nº 69 13-34
hsa-mir-101-1
SEC ID Nº 70 47-68
hsa-mir-101-2
SEC ID Nº 71 49-70
hsa-mir-103-2
SEC ID Nº 72 48-70
hsa-mir-103-1
SEC ID Nº 73 48-70
hsa-mir-105-1
SEC ID Nº 74 13-32
hsa-mir-105-2
SEC ID Nº 75 13-32
hsa-mir-106a
SEC ID Nº 76 13-36
hsa-mir-106b
SEC ID Nº 77 12-32
hsa-mir-107
SEC ID Nº 78 50-72
hsa-mir-122a
SEC ID Nº 79 15-37
12
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-124a-1
SEC ID Nº 80 52-73
hsa-mir-124a-2
SEC ID Nº 81 61-82
hsa-mir-124a-3
SEC ID Nº 82 52-73
hsa-mir-125b-1
SEC ID Nº 83 15-36
hsa-mir-125a
SEC ID Nº 84 15-37
hsa-mir-125b-2
SEC ID Nº 85 17-38
hsa-mir-126
SEC ID Nº 86 15-35 y/o 52-72
hsa-mir-127
SEC ID Nº 87 57-78
hsa-mir-128a
SEC ID Nº 88 50-71
hsa-mir-128b
SEC ID Nº 89 52-73
hsa-mir-129-2
SEC ID Nº 90 15-35
hsa-mir-130a
SEC ID Nº 91 55-74
hsa-mir-130b
SEC ID Nº 92 51-72
hsa-mir-132
SEC ID Nº 93 59-80
hsa-mir-133a-1
SEC ID Nº 94 54-75
hsa-mir-133a-2
SEC ID Nº 95 60-81
hsa-mir-133b
SEC ID Nº 96 67-87
hsa-mir-134
SEC ID Nº 97 8-28
hsa-mir-135a-1
SEC ID Nº 98 17-39
hsa-mir-135a-2
SEC ID Nº 99 23-45
hsa-mir-135b
SEC ID Nº 100 16-37
hsa-mir-136
SEC ID Nº 101 15-37
hsa-mir-137
SEC ID Nº 102 60-81
hsa-mir-138-2
SEC ID Nº 103 10-26
hsa-mir-138-1
SEC ID Nº 104 23-39
hsa-mir-139
SEC ID Nº 105 7-24
hsa-mir-140
SEC ID Nº 106 24-44
hsa-mir-141
SEC ID Nº 107 60-80
hsa-mir-142
SEC ID Nº 108 16-35 y/o 52-74
hsa-mir-143
SEC ID Nº 109 61-82
hsa-mir-144
SEC ID Nº 110 52-73
hsa-mir-145
SEC ID Nº 111 16-39
hsa-mir-146
SEC ID Nº 112 21-42
hsa-mir-147
SEC ID Nº 113 47-66
hsa-mir-148a
SEC ID Nº 114 44-65
hsa-mir-148b
SEC ID Nº 115 63-84
hsa-mir-149
SEC ID Nº 116 15-36
hsa-mir-150
SEC ID Nº 117 16-37
hsa-mir-151
SEC ID Nº 118 46-67
hsa-mir-152
SEC ID Nº 119 54-74
hsa-mir-153-1
SEC ID Nº 120 54-73
13
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-153-2
SEC ID Nº 121 53-72
hsa-mir-154
SEC ID Nº 122 15-36
hsa-mir-155
SEC ID Nº 123 4-25
hsa-mir-181a
SEC ID Nº 124 39-61
hsa-mir-181b-1
SEC ID Nº 125 36-59
hsa-mir-181c
SEC ID Nº 126 27-48
hsa-mir-181b-2
SEC ID Nº 127 16-39
hsa-mir-182
SEC ID Nº 128 23-44 y/o 67-87
hsa-mir-183
SEC ID Nº 129 27-49
hsa-mir-184
SEC ID Nº 130 53-74
hsa-mir-185
SEC ID Nº 131 15-32
hsa-mir-186
SEC ID Nº 132 15-37
hsa-mir-187
SEC ID Nº 133 71-91
hsa-mir-188
SEC ID Nº 134 15-36
hsa-mir-190
SEC ID Nº 135 15-36
hsa-mir-191
SEC ID Nº 136 16-37
hsa-mir-192
SEC ID Nº 137 24-44
hsa-mir-193
SEC ID Nº 138 55-75
hsa-mir-194-1
SEC ID Nº 139 15-36
hsa-mir-194-2
SEC ID Nº 140 15-36
hsa-mir-195
SEC ID Nº 141 15-35
hsa-mir-196-1
SEC ID Nº 142 7-27
hsa-mir-196-2
SEC ID Nº 143 25-45
hsa-mir-197
SEC ID Nº 144 48-69
hsa-mir-198
SEC ID Nº 145 6-24
hsa-mir-199a-1
SEC ID Nº 146 6-28 y/o 46-67
hsa-mir-199a-2
SEC ID Nº 147 31-53 y/o 69-90
hsa-mir-199b
SEC ID Nº 148 26-48
hsa-mir-200b
SEC ID Nº 149 54-77
hsa-mir-200c
SEC ID Nº 150 45-66
hsa-mir-200a
SEC ID Nº 151 54-75
hsa-mir-203
SEC ID Nº 152 65-86
hsa-mir-204
SEC ID Nº 153 33-54
hsa-mir-205
SEC ID Nº 154 34-55
hsa-mir-206
SEC ID Nº 155 53-74
hsa-mir-208
SEC ID Nº 156 44-65
hsa-mir-210
SEC ID Nº 157 66-86
hsa-mir-211
SEC ID Nº 158 26-47
hsa-mir-212
SEC ID Nº 159 71-91
hsa-mir-213
SEC ID Nº 160 24-46 y/o 64-85
hsa-mir-214
SEC ID Nº 161 71-91
14
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-215
SEC ID Nº 162 27-47
hsa-mir-216
SEC ID Nº 163 19-39
hsa-mir-217
SEC ID Nº 164 35-58
hsa-mir-218-1
SEC ID Nº 165 25-45
hsa-mir-218-2
SEC ID Nº 166 25-45
hsa-mir-219-1
SEC ID Nº 167 21-41
hsa-mir-219-2
SEC ID Nº 168 19-39
hsa-mir-220
SEC ID Nº 169 23-43
hsa-mir-221
SEC ID Nº 170 65-87
hsa-mir-222
SEC ID Nº 171 69-92
hsa-mir-223
SEC ID Nº 172 68-88
hsa-mir-224
SEC ID Nº 173 8-30
hsa-mir-296
SEC ID Nº 174 14-34
hsa-mir-299
SEC ID Nº 175 7-28
hsa-mir-301
SEC ID Nº 176 51-73
hsa-mir-302
SEC ID Nº 177 44-66
hsa-mir-320
SEC ID Nº 178 48-70
hsa-mir-321
SEC ID Nº 179 10-30
hsa-mir-323
SEC ID Nº 180 50-71
hsa-mir-324
SEC ID Nº 181 16-38 y/o 51-72
hsa-mir-326
SEC ID Nº 182 60-79
hsa-mir-328
SEC ID Nº 183 48-69
hsa-mir-330
SEC ID Nº 184 57-79
hsa-mir-331
SEC ID Nº 185 61-81
hsa-mir-335
SEC ID Nº 186 16-38
hsa-mir-337
SEC ID Nº 187 56-78
hsa-mir-338
SEC ID Nº 188 42-64
hsa-mir-339
SEC ID Nº 189 15-35
hsa-mir-340
SEC ID Nº 190 58-80
hsa-mir-342
SEC ID Nº 191 61-84
hsa-mir-345
SEC ID Nº 573 17-37
hsa-mir-346
SEC ID Nº 574 4-26
hsa-mir-367
SEC ID Nº 575 44-65
hsa-mir-368
SEC ID Nº 576 44-65
hsa-mir-369
SEC ID Nº 577 44-64
hsa-mir-370
SEC ID Nº 578 48-68
hsa-mir-371
SEC ID Nº 579 44-64
hsa-mir-372
SEC ID Nº 580 42-64
hsa-mir-373
SEC ID Nº 581 44-66
hsa-mir-374
SEC ID Nº 582 12-33
hsa-mir-375
SEC ID Nº 677 40-61
15
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-376a
SEC ID Nº 678 44-64
hsa-mir-377
SEC ID Nº 679 45-66
hsa-mir-378
SEC ID Nº 680 5-26 y 44-65
hsa-mir-379
SEC ID Nº 681 6-24
hsa-mir-380
SEC ID Nº 682 5-26 y 40-61
hsa-mir-381
SEC ID Nº 683 49-70
hsa-mir-382
SEC ID Nº 684 11-32
hsa-mir-383
SEC ID Nº 685 7-28
hsa-mir-384
SEC ID Nº 686 57-76
hsa-mir-422a
SEC ID Nº 687 11-32
hsa-mir-423
SEC ID Nº 688 53-74
hsa-mir-424
SEC ID Nº 689 11-32
hsa-mir-425
SEC ID Nº 690 55-75
hsa-mir-448
SEC ID Nº 691 71-92
hsa-mir-429
SEC ID Nº 692 51-72
hsa-mir-449
SEC ID Nº 693 16-37
hsa-mir-450-1
SEC ID Nº 694 17-38
hsa-mir-450-2
SEC ID Nº 704 22-43
hsa-mir-451
SEC ID Nº 705 17-39
hsa-mir-452
SEC ID Nº 706 17-38
hsa-mir-453
SEC ID Nº 707 43-64
hsa-mir-455
SEC ID Nº 708 16-37
hsa-mir-483
SEC ID Nº 709 48-70
hsa-mir-484
SEC ID Nº 710 2-23
hsa-mir-485
SEC ID Nº 711 9-30
hsa-mir-486
SEC ID Nº 712 4-25
hsa-mir-487
SEC ID Nº 713 49-70
hsa-mir-488
SEC ID Nº 714 14-34
hsa-mir-489
SEC ID Nº 715 51-73
hsa-mir-490
SEC ID Nº 716 76-97
hsa-mir-491
SEC ID Nº 717 16-38
hsa-mir-492
SEC ID Nº 718 30-52
hsa-mir-493
SEC ID Nº 719 16-37
hsa-mir-494
SEC ID Nº 720 48-71
hsa-mir-495
SEC ID Nº 721 50-72
hsa-mir-496
SEC ID Nº 722 61-77
hsa-mir-497
SEC ID Nº 723 24-44
hsa-mir-498
SEC ID Nº 724 34-56
hsa-mir-499
SEC ID Nº 725 33-55
hsa-mir-500
SEC ID Nº 726 52-73
hsa-mir-501
SEC ID Nº 727 14-35
16
E10183538
17-09-2014
(continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-502
SEC ID Nº 728 1-21
hsa-mir-503
SEC ID Nº 729 6-28
hsa-mir-504
SEC ID Nº 730 13-33
hsa-mir-505
SEC ID Nº 731 52-73
hsa-mir-506
SEC ID Nº 732 71-91
hsa-mir-507
SEC ID Nº 733 56-76
hsa-mir-508
SEC ID Nº 734 61-83
hsa-mir-509
SEC ID Nº 735 55-77
hsa-mir-510
SEC ID Nº 736 10-32
hsa-mir-511-1
SEC ID Nº 737 16-36
hsa-mir-511-2
SEC ID Nº 738 16-36
hsa-mir-512-1
SEC ID Nº 739 14-36
hsa-mir-512-2
SEC ID Nº 740 20-42
hsa-mir-513-1
SEC ID Nº 741 37-58
hsa-mir-513-2
SEC ID Nº 742 36-57
hsa-mir-514-1
SEC ID Nº 743 39-58
hsa-mir-514-2
SEC ID Nº 744 39-58
hsa-mir-514-3
SEC ID Nº 745 39-58
hsa-mir-515-1
SEC ID Nº 746 14-37
hsa-mir-515-2
SEC ID Nº 747 14-37
hsa-mir-516-1
SEC ID Nº 748 61-78
hsa-mir-516-2
SEC ID Nº 749 61-78
hsa-mir-516-3
SEC ID Nº 750 15-37
hsa-mir-516-4
SEC ID Nº 751 15-37
hsa-mir-517a
SEC ID Nº 752 15-36
hsa-mir-517b
SEC ID Nº 753 6-27
hsa-mir-517c
SEC ID Nº 754 20-41
hsa-mir-518a-1
SEC ID Nº 755 14-34
hsa-mir-518a-2
SEC ID Nº 756 15-34
hsa-mir-518b
SEC ID Nº 757 51-72
hsa-mir-518c
SEC ID Nº 758 24-46
hsa-mir-518d
SEC ID Nº 759 16-36
hsa-mir-518e
SEC ID Nº 760 54-75
hsa-mir-518f
SEC ID Nº 761 16-38
hsa-mir-519a-1
SEC ID Nº 762 15-38
hsa-mir-519a-2
SEC ID Nº 763 54-78
hsa-mir-519b
SEC ID Nº 764 13-36
hsa-mir-519c
SEC ID Nº 765 16-39
hsa-mir-519d
SEC ID Nº 766 54-76
hsa-mir-519e
SEC ID Nº 767 14-35
hsa-mir-520a
SEC ID Nº 768 15-35
17
imagen10
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-7-1
SEC ID Nº 205 24-44
mmu-mir-7-2
SEC ID Nº 206 19-39
mmu-mir-7b
SEC ID Nº 207 30-50
mmu-mir-9-2
SEC ID Nº 208 8-30 y/o 46-66
mmu-mir-9-1
SEC ID Nº 209 16-38 y/o 56-76
mmu-mir-9-3
SEC ID Nº 210 16-38 y/o 56-76
mmu-mir-10b
SEC ID Nº 211 7-28
mmu-mir-10a-1
SEC ID Nº 212 22-44
mmu-mir-10a-2
SEC ID Nº 213 22-44
mmu-mir-15b
SEC ID Nº 214 4-25
mmu-mir-15a
SEC ID Nº 215 15-36
mmu-mir-16-1
SEC ID Nº 216 16-37
mmu-mir-16-2
SEC ID Nº 217 17-38
mmu-mir-17
SEC ID Nº 218 14-37 y/o 51-70
mmu-mir-18
SEC ID Nº 219 17-38
mmu-mir-19b-2
SEC ID Nº 220 54-76
mmu-mir-19a
SEC ID Nº 221 49-71
mmu-mir-19b-1
SEC ID Nº 222 54-76
mmu-mir-20
SEC ID Nº 223 27-49
mmu-mir-21
SEC ID Nº 224 18-39
mmu-mir-22
SEC ID Nº 225 57-78
mmu-mir-23b
SEC ID Nº 226 46-68
mmu-mir-23a
SEC ID Nº 227 46-66
mmu-mir-24-1
SEC ID Nº 228 6-28 y/o 44-65
mmu-mir-24-2
SEC ID Nº 229 61-82
mmu-mir-25
SEC ID Nº 230 52-73
mmu-mir-26a-1
SEC ID Nº 231 16-37
mmu-mir-26b
SEC ID Nº 232 15-36
mmu-mir-26a-2
SEC ID Nº 233 14-35
mmu-mir-27b
SEC ID Nº 234 49-68
mmu-mir-27a
SEC ID Nº 235 56-76
mmu-mir-28
SEC ID Nº 236 14-35
mmu-mir-29b-1
SEC ID Nº 237 47-68
mmu-mir-29a
SEC ID Nº 238 53-74
19
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-29c
SEC ID Nº 239 54-75
mmu-mir-29b-2
SEC ID Nº 240 52-73
mmu-mir-30a
SEC ID Nº 241 47-68
mmu-mir-30b
SEC ID Nº 242 2-22
mmu-mir-30e
SEC ID Nº 243 2-21
mmu-mir-30c-1
SEC ID Nº 244 17-39
mmu-mir-30c-2
SEC ID Nº 245 14-36
mmu-mir-30d
SEC ID Nº 246 12-33
mmu-mir-31
SEC ID Nº 247 28-49
mmu-mir-32
SEC ID Nº 248 6-26
mmu-mir-33
SEC ID Nº 249 6-24
mmu-mir-34c
SEC ID Nº 250 13-35
mmu-mir-34b
SEC ID Nº 251 13-35
mmu-mir-34a
SEC ID Nº 252 20-42
mmu-mir-92-2
SEC ID Nº 253 55-75
mmu-mir-92-1
SEC ID Nº 254 50-70
mmu-mir-93
SEC ID Nº 255 15-37
mmu-mir-96
SEC ID Nº 256 24-46
mmu-mir-98
SEC ID Nº 257 2-23
mmu-mir-99a
SEC ID Nº 258 6-25
mmu-mir-99b
SEC ID Nº 259 7-28
mmu-mir-100
SEC ID Nº 260 13-34
mmu-mir-101
SEC ID Nº 261 38-57
mmu-mir-101b
SEC ID Nº 262 61-82
mmu-mir-103-1
SEC ID Nº 263 52-74
mmu-mir-103-2
SEC ID Nº 264 52-74
mmu-mir-106a
SEC ID Nº 265 5-26
mmu-mir-106b
SEC ID Nº 266 12-32
mmu-mir-107
SEC ID Nº 267 52-74
mmu-mir-122a
SEC ID Nº 268 6-28
mmu-mir-124a-3
SEC ID Nº 269 43-64
mmu-mir-124a-1
SEC ID Nº 270 52-73
mmu-mir-124a-2
SEC ID Nº 271 61-82
mmu-mir-125a
SEC ID Nº 272 6-28
mmu-mir-125b-2
SEC ID Nº 273 7-28
20
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-125b-1
SEC ID Nº 274 15-36
mmu-mir-126
SEC ID Nº 275 9-29 y/o 46-66
mmu-mir-127
SEC ID Nº 276 43-64
mmu-mir-128a
SEC ID Nº 277 44-65
mmu-mir-128b
SEC ID Nº 278 48-69
mmu-mir-129-1
SEC ID Nº 279 6-27
mmu-mir-129-2
SEC ID Nº 280 15-36
mmu-mir-130a
SEC ID Nº 281 42-61
mmu-mir-130b
SEC ID Nº 282 51-72
mmu-mir-132
SEC ID Nº 283 42-63
mmu-mir-133a-1
SEC ID Nº 284 44-65
mmu-mir-133a-2
SEC ID Nº 285 60-81
mmu-mir-133b
SEC ID Nº 286 67-87
mmu-mir-134
SEC ID Nº 287 7-27
mmu-mir-135a-1
SEC ID Nº 288 17-39
mmu-mir-135b
SEC ID Nº 289 16-37
mmu-mir-135a-2
SEC ID Nº 290 23-45
mmu-mir-136
SEC ID Nº 291 5-27
mmu-mir-137
SEC ID Nº 292 46-67
mmu-mir-138-2
SEC ID Nº 293 2-18
mmu-mir-138-1
SEC ID Nº 294 23-39
mmu-mir-139
SEC ID Nº 295 7-24
mmu-mir-140
SEC ID Nº 296 7-27
mmu-mir-141
SEC ID Nº 297 49-69
mmu-mir-142
SEC ID Nº 298 4-23 y/o 40-61
mmu-mir-143
SEC ID Nº 299 40-61
mmu-mir-144
SEC ID Nº 300 43-64
mmu-mir-145
SEC ID Nº 301 7-30
mmu-mir-146
SEC ID Nº 302 6-27
mmu-mir-148a
SEC ID Nº 303 61-82
mmu-mir-149
SEC ID Nº 304 4-25
mmu-mir-150
SEC ID Nº 305 6-27
mmu-mir-151
SEC ID Nº 306 43-63
mmu-mir-152
SEC ID Nº 307 47-67
mmu-mir-153
SEC ID Nº 308 44-63
21
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-154
SEC ID Nº 309 6-27
mmu-mir-155
SEC ID Nº 310 4-25
mmu-mir-181a
SEC ID Nº 311 7-29
mmu-mir-181b-1
SEC ID Nº 312 12-35
mmu-mir-181c
SEC ID Nº 313 17-38
mmu-mir-181b-2
SEC ID Nº 314 16-39
mmu-mir-182
SEC ID Nº 315 7-28
mmu-mir-183
SEC ID Nº 316 6-28
mmu-mir-184
SEC ID Nº 317 45-66
mmu-mir-185
SEC ID Nº 318 7-24
mmu-mir-186
SEC ID Nº 319 7-29
mmu-mir-187
SEC ID Nº 320 40-61
mmu-mir-188
SEC ID Nº 321 6-27
mmu-mir-190
SEC ID Nº 322 6-27
mmu-mir-191
SEC ID Nº 323 7-28
mmu-mir-192
SEC ID Nº 324 14-31
mmu-mir-193
SEC ID Nº 325 41-61
mmu-mir-194-1
SEC ID Nº 326 7-28
mmu-mir-194-2
SEC ID Nº 327 16-37
mmu-mir-195
SEC ID Nº 328 1-21
mmu-mir-196-1
SEC ID Nº 329 24-44
mmu-mir-196-2
SEC ID Nº 330 16-36
mmu-mir-199a-1
SEC ID Nº 331 6-28 y/o 45-66
mmu-mir-199a-2
SEC ID Nº 332 31-53 y/o 69-90
mmu-mir-199b
SEC ID Nº 333 26-48
mmu-mir-200b
SEC ID Nº 334 45-67
mmu-mir-200a
SEC ID Nº 335 54-75
mmu-mir-200c
SEC ID Nº 336 46-67
mmu-mir-201
SEC ID Nº 337 6-26
mmu-mir-202
SEC ID Nº 338 45-66
mmu-mir-203
SEC ID Nº 339 49-69
mmu-mir-204
SEC ID Nº 340 6-28
mmu-mir-205
SEC ID Nº 341 7-28
mmu-mir-206
SEC ID Nº 342 46-67
mmu-mir-207
SEC ID Nº 343 52-74
22
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-208
SEC ID Nº 344 50-71
mmu-mir-210
SEC ID Nº 345 66-86
mmu-mir-211
SEC ID Nº 346 26-47
mmu-mir-212
SEC ID Nº 347 56-76
mmu-mir-213
SEC ID Nº 348 14-36 y/o 54-75
mmu-mir-214
SEC ID Nº 349 71-91
mmu-mir-215
SEC ID Nº 350 30-50
mmu-mir-216
SEC ID Nº 351 7-27
mmu-mir-217
SEC ID Nº 352 34-57
mmu-mir-218-2
SEC ID Nº 353 25-45
mmu-mir-219-1
SEC ID Nº 354 21-41
mmu-mir-219-2
SEC ID Nº 355 19-39
mmu-mir-221
SEC ID Nº 356 60-81
mmu-mir-222
SEC ID Nº 357 49-71
mmu-mir-223
SEC ID Nº 358 68-88
mmu-mir-224
SEC ID Nº 359 8-30
mu-miR-290
SEC ID Nº 360 15-37
mmu-mir-291
SEC ID Nº 361 14-35 y/o 50-72
mmu-mir-292
SEC ID Nº 362 12-33 y/o 51-73
mmu-mir-293
SEC ID Nº 363 48-69
mmu-mir-294
SEC ID Nº 364 51-72
mmu-mir-295
SEC ID Nº 365 43-65
mmu-mir-296
SEC ID Nº 366 13-33
mmu-mir-297-1
SEC ID Nº 367 15-35
mmu-mir-297-2
SEC ID Nº 368 36-56
mmu-mir-298
SEC ID Nº 369 11-32
mmu-mir-299
SEC ID Nº 370 7-28
mmu-mir-300
SEC ID Nº 371 51-72
mmu-mir-301
SEC ID Nº 372 51-73
mmu-mir-302
SEC ID Nº 373 44-66
mmu-mir-320
SEC ID Nº 374 48-70
mmu-mir-321
SEC ID Nº 375 10-30
mmu-mir-323
SEC ID Nº 376 50-71
mmu-mir-324
SEC ID Nº 377 18-40 y/o 53-74
mmu-mir-325
SEC ID Nº 378 16-38
23
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-326
SEC ID Nº 379 60-80
mmu-mir-328
SEC ID Nº 380 61-82
mmu-mir-329
SEC ID Nº 381 61-82
mmu-mir-330
SEC ID Nº 382 61-83
mmu-mir-331
SEC ID Nº 383 61-81
mmu-mir-337
SEC ID Nº 384 61-83
mmu-mir-338
SEC ID Nº 385 61-83
mmu-mir-339
SEC ID Nº 386 16-36
mmu-mir-340
SEC ID Nº 387 61-83
mmu-mir-341
SEC ID Nº 388 61-81
mmu-mir-342
SEC ID Nº 389 61-84
mmu-mir-344
SEC ID Nº 390 61-83
mmu-mir-345
SEC ID Nº 391 16-36
mmu-mir-346
SEC ID Nº 392 16-38
mmu-mir-350
SEC ID Nº 393 61-84
mmu-mir-351
SEC ID Nº 583 16-39
mmu-mir-370
SEC ID Nº 584 48-70
mmu-mir-376a
SEC ID Nº 585 44-64
mmu-mir-376b
SEC ID Nº 586 51-72
mmu-mir-380
SEC ID Nº 587 40-61
mmu-mir-409
SEC ID Nº 588 47-69
mmu-mir-410
SEC ID Nº 589 50-71
mmu-mir-411
SEC ID Nº 590 56-78
mmu-mir-412
SEC ID Nº 591 50-72
mmu-mir-425
SEC ID Nº 695 54-74
mmu-mir-429
SEC ID Nº 696 51-72
mmu-mir-448
SEC ID Nº 697 72-93
mmu-mir-449
SEC ID Nº 698 16-37
mmu-mir-450
SEC ID Nº 699 17-38
mmu-mir-451
SEC ID Nº 786 17-38
mmu-mir-452
SEC ID Nº 787 17-38
mmu-mir-463
SEC ID Nº 788 4-24
mmu-mir-464
SEC ID Nº 789 47-69
mmu-mir-465
SEC ID Nº 790 5-27
mmu-mir-466
SEC ID Nº 791 51-73
24
E10183538
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-467
SEC ID Nº 792 50-71
mmu-mir-468
SEC ID Nº 793 53-75
mmu-mir-469
SEC ID Nº 794 6-31
mmu-mir-470
SEC ID Nº 795 9-29
mmu-mir-471
SEC ID Nº 796 7-29
mmu-mir-483
SEC ID Nº 797 45-67
mmu-mir-484
SEC ID Nº 798 2-23
mmu-mir-485
SEC ID Nº 799 9-30
mmu-mir-486
SEC ID Nº 800 4-25
Tabla 3
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-let-7d
SEC ID Nº 394 14-34 y/o 68-89
mo-mir-7-1
SEC ID Nº 395 19-39 y/o 61-82
mo-let-7a-1
SEC ID Nº 396 13-34
mo-let-7a-2
SEC ID Nº 397 17-38
mo-let-7b
SEC ID Nº 398 7-28
mo-let-7c-1
SEC ID Nº 399 16-37
mo-let-7c-2
SEC ID Nº 400 14-35
mo-let-7e
SEC ID Nº 401 15-35
mo-let-7f-1
SEC ID Nº 402 8-29
mo-let-7f-2
SEC ID Nº 403 8-29
mo-let-7i
SEC ID Nº 404 6-24
mo-mir-7-2
SEC ID Nº 405 19-39
mo-mir-7b
SEC ID Nº 406 29-49
mo-mir-9-1
SEC ID Nº 407 16-38
mo-mir-9-3
SEC ID Nº 408 16-38
mo-mir-9-2
SEC ID Nº 409 16-38
mo-mir-10a
SEC ID Nº 410 22-44
mo-mir-10b
SEC ID Nº 411 26-47
mo-mir-15b
SEC ID Nº 412 20-41
mo-mir-16
SEC ID Nº 413 17-38
mo-mir-17
SEC ID Nº 414 14-37
25
E10183538
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-mir-18
SEC ID Nº 415 17-38
mo-mir-19b-1
SEC ID Nº 416 54-76
mo-mir-19b-2
SEC ID Nº 417 62-84
mo-mir-19a
SEC ID Nº 418 49-71
mo-mir-20
SEC ID Nº 419 16-38 y/o 52-72
mo-mir-21
SEC ID Nº 420 18-39
mo-mir-22
SEC ID Nº 421 57-78
mo-mir-23a
SEC ID Nº 422 46-66
mo-mir-23b
SEC ID Nº 423 58-80
mo-mir-24-1
SEC ID Nº 424 44-65
mo-mir-24-2
SEC ID Nº 425 61-82
mo-mir-25
SEC ID Nº 426 52-73
mo-mir-26a
SEC ID Nº 427 16-37
mo-mir-26b
SEC ID Nº 428 15-36
mo-mir-27b
SEC ID Nº 429 61-80
mo-mir-27a
SEC ID Nº 430 56-76
mo-mir-28
SEC ID Nº 431 14-35
mo-mir-29b-2
SEC ID Nº 432 52-73
mo-mir-29a
SEC ID Nº 433 53-74
mo-mir-29b-1
SEC ID Nº 434 51-72
mo-mir-29c
SEC ID Nº 435 54-75
mo-mir-30c-1
SEC ID Nº 436 17-39
mo-mir-30e
SEC ID Nº 437 2-21
mo-mir-30b
SEC ID Nº 438 16-36
mo-mir-30d
SEC ID Nº 439 12-33
mo-mir-30a
SEC ID Nº 440 47-68
mo-mir-30c-2
SEC ID Nº 441 14-36
mo-mir-31
SEC ID Nº 442 28-49
mo-mir-32
SEC ID Nº 443 6-26
mo-mir-33
SEC ID Nº 444 6-24
mo-mir-34b
SEC ID Nº 445 13-35
mo-mir-34c
SEC ID Nº 446 13-35
mo-mir-34a
SEC ID Nº 447 20-42
mo-mir-92-1
SEC ID Nº 448 48-68
26
E10183538
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-mir-92-2
SEC ID Nº 449 55-75
mo-mir-93
SEC ID Nº 450 15-37
mo-mir-96
SEC ID Nº 451 24-46
mo-mir-98
SEC ID Nº 452 2-23
mo-mir-99a
SEC ID Nº 453 13-34
mo-mir-99b
SEC ID Nº 454 7-28
mo-mir-100
SEC ID Nº 455 13-34
mo-mir-101b
SEC ID Nº 456 61-82
mo-mir-101
SEC ID Nº 457 47-68
mo-mir-103-2
SEC ID Nº 458 52-74
mo-mir-103-1
SEC ID Nº 459 52-74
mo-mir-106b
SEC ID Nº 460 12-32
mo-mir-107
SEC ID Nº 461 52-74
mo-mir-122a
SEC ID Nº 462 15-37
mo-mir-124a-3
SEC ID Nº 463 52-73
mo-mir-124a-1
SEC ID Nº 464 52-73
mo-mir-124a-2
SEC ID Nº 465 61-82
mo-mir-125a
SEC ID Nº 466 15-37
mo-mir-125b-1
SEC ID Nº 467 15-36
mo-mir-125b-2
SEC ID Nº 468 17-38
mo-mir-126
SEC ID Nº 469 9-29 y/o 46-66
mo-mir-127
SEC ID Nº 470 57-78
mo-mir-128a
SEC ID Nº 471 50-71
mo-mir-128b
SEC ID Nº 472 52-73
mo-mir-129-2
SEC ID Nº 473 19-40 y/o 61-82
mo-mir-129-1
SEC ID Nº 474 6-27
mo-mir-130a
SEC ID Nº 475 55-74
mo-mir-130b
SEC ID Nº 476 51-72
mo-mir-132
SEC ID Nº 477 59-80
mo-mir-133a
SEC ID Nº 478 53-74
mo-mir-134
SEC ID Nº 479 8-28
mo-mir-135b
SEC ID Nº 480 16-37
mo-mir-135a
SEC ID Nº 481 23-45
mo-mir-136
SEC ID Nº 482 15-37
mo-mir-137
SEC ID Nº 483 60-81
27
E10183538
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-mir-138-2
SEC ID Nº 484 9-25
mo-mir-138-1
SEC ID Nº 485 23-39
mo-mir-139
SEC ID Nº 486 7-24
mo-mir-140
SEC ID Nº 487 23-43 y/o 61-84
mo-mir-141
SEC ID Nº 488 59-79
mo-mir-142
SEC ID Nº 489 16-35 y/o 52-74
mo-mir-143
SEC ID Nº 490 60-81
mo-mir-144
SEC ID Nº 491 50-71
mo-mir-145
SEC ID Nº 492 16-39
mo-mir-146
SEC ID Nº 493 17-38
mo-mir-148b
SEC ID Nº 494 61-82
mo-mir-150
SEC ID Nº 495 16-37
mo-mir-151
SEC ID Nº 496 16-37 y/o 50-71
mo-mir-152
SEC ID Nº 497 53-73
mo-mir-153
SEC ID Nº 498 53-72
mo-mir-154
SEC ID Nº 499 15-36
mo-mir-181c
SEC ID Nº 500 24-45
mo-mir-181a
SEC ID Nº 501 39-61
mo-mir-181b-1
SEC ID Nº 502 36-59
mo-mir-181b-2
SEC ID Nº 503 15-38
mo-mir-183
SEC ID Nº 504 27-49
mo-mir-184
SEC ID Nº 505 47-68
mo-mir-185
SEC ID Nº 506 14-31
mo-mir-186
SEC ID Nº 507 15-37
mo-mir-187
SEC ID Nº 508 66-86
mo-mir-190
SEC ID Nº 509 15-36
mo-mir-191
SEC ID Nº 510 15-36
mo-mir-192
SEC ID Nº 511 24-44
mo-mir-193
SEC ID Nº 512 54-74
mo-mir-194-1
SEC ID Nº 513 15-36
mo-mir-194-2
SEC ID Nº 514 15-36
mo-mir-195
SEC ID Nº 515 15-35
mo-mir-196
SEC ID Nº 516 25-45
mo-mir-199a
SEC ID Nº 517 31-53
mo-mir-200c
SEC ID Nº 518 46-67
28
E10183538
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-mir-200a
SEC ID Nº 519 54-75
mo-mir-200b
SEC ID Nº 520 54-77
mo-mir-203
SEC ID Nº 521 52-73
mo-mir-204
SEC ID Nº 522 33-54
mo-mir-205
SEC ID Nº 523 33-54
mo-mir-206
SEC ID Nº 524 51-72
mo-mir-208
SEC ID Nº 525 50-71
mo-mir-210
SEC ID Nº 526 66-86
mo-mir-211
SEC ID Nº 527 26-47
mo-mir-212
SEC ID Nº 528 72-92
mo-mir-213
SEC ID Nº 529 55-76
mo-mir-214
SEC ID Nº 530 71-91
mo-mir-216
SEC ID Nº 531 19-39
mo-mir-217
SEC ID Nº 532 32-55
mo-mir-218-2
SEC ID Nº 533 25-45
mo-mir-218-1
SEC ID Nº 534 25-45
mo-mir-219-1
SEC ID Nº 535 21-41
mo-mir-219-2
SEC ID Nº 536 19-39
mo-mir-221
SEC ID Nº 537 65-87
mo-mir-222
SEC ID Nº 538 62-85
mo-mir-223
SEC ID Nº 539 68-88
mo-mir-290
SEC ID Nº 540 14-36
mo-mir-291
SEC ID Nº 541 14-35 y/o 50-72
mo-mir-292
SEC ID Nº 542 12-33 y/o 51-73
mo-mir-296
SEC ID Nº 543 13-33
mo-mir-297
SEC ID Nº 544 26-48
mo-mir-298
SEC ID Nº 545 11-32
mo-mir-299
SEC ID Nº 546 7-28
mo-mir-300
SEC ID Nº 547 51-72
mo-mir-301
SEC ID Nº 548 61-85
mo-mir-320
SEC ID Nº 549 48-70
mo-mir-321
SEC ID Nº 550 10-30
mo-mir-322
SEC ID Nº 551 61-80
mo-mir-323
SEC ID Nº 552 50-71
mo-mir-324
SEC ID Nº 553 16-38 y/o 51-72
29
E10183538
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mo-mir-325
SEC ID Nº 554 16-38
mo-mir-326
SEC ID Nº 555 60-80
mo-mir-328
SEC ID Nº 556 48-69
mo-mir-329
SEC ID Nº 557 61-82
mo-mir-330
SEC ID Nº 558 60-82
mo-mir-3 31
SEC ID Nº 559 61-81
mo-mir-333
SEC ID Nº 560 16-35
mo-mir-336
SEC ID Nº 561 16-36
mo-mir-337
SEC ID Nº 562 60-82
mo-mir-338
SEC ID Nº 563 41-63
mo-mir-339
SEC ID Nº 564 16-36
mo-mir-341
SEC ID Nº 565 61-81
mo-mir-342
SEC ID Nº 566 61-84
mo-mir-344
SEC ID Nº 567 61-83
mo-mir-345
SEC ID Nº 568 16-36
mo-mir-346
SEC ID Nº 569 16-38
mo-mir-349
SEC ID Nº 570 61-82
mo-mir-350
SEC ID Nº 571 61-84
mo-mir-351
SEC ID Nº 572 16-39
mo-mir-352
SEC ID Nº 592 61-81
mo-mir-421
SEC ID Nº 593 10-30
mo-mir-429
SEC ID Nº 700 53-74
mo-mir-448
SEC ID Nº 701 72-93
mo-mir-449
SEC ID Nº 702 16-37
mo-mir-450
SEC ID Nº 703 17-38
mo-mir-451
SEC ID Nº 801 17-38
mo-mir-483
SEC ID Nº 802 45-67
Se entiende que un miARN se deriva de secuencias genómicas de un gen. A este respecto, el término “gen” se utiliza por simplicidad para referirse a la secuencia genómica que codifica el precursor de miARN de un determinado miARN. Sin embargo, las realizaciones de la invención puede implicar secuencias genómicas de un miARN que está 5 implicado en su expresión, tal como un promotor u otras secuencias reguladoras.
El término “recombinante” se puede utilizar y generalmente se refiere a una molécula que se ha modificado in vitro o que es el producto replicado o expresado de tal molécula.
La expresión “ácido nucleico” se conoce bien en la técnica. Un “ácido nucleico” como se utiliza en el presente documento generalmente se refiere a una molécula (de una o más cadenas) de ADN, ARN o un derivado o análogo 10 del mismo, que comprende una base nitrogenada. Una base nitrogenada incluye, por ejemplo, una base purínica o pirimidínica de origen natural en el ADN (por ejemplo, una adenina “A”, una guanina “G”, una timina “T” o una
30
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50

Claims (1)

  1. imagen1
    condición de que se excluyan los procedimientos para el tratamiento del cuerpo humano o animal por medio de cirugía como terapia.
    201
ES10183538.7T 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN Active ES2503742T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62717104P 2004-11-12 2004-11-12
US627171P 2004-11-12
US64963405P 2005-02-03 2005-02-03
US649634P 2005-02-03
US68373605P 2005-05-23 2005-05-23
US683736P 2005-05-23

Publications (1)

Publication Number Publication Date
ES2503742T3 true ES2503742T3 (es) 2014-10-07

Family

ID=37570916

Family Applications (13)

Application Number Title Priority Date Filing Date
ES10183490.1T Active ES2534301T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2T Active ES2503738T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183481.0T Active ES2503739T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2T Active ES2503765T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6T Active ES2503741T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5T Active ES2534304T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183543.7T Active ES2503743T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183589.0T Active ES2534303T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0T Active ES2534300T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6T Active ES2534302T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183525.4T Active ES2503740T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183538.7T Active ES2503742T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183577.5T Active ES2507544T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications Before (11)

Application Number Title Priority Date Filing Date
ES10183490.1T Active ES2534301T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2T Active ES2503738T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183481.0T Active ES2503739T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2T Active ES2503765T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6T Active ES2503741T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5T Active ES2534304T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183543.7T Active ES2503743T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183589.0T Active ES2534303T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0T Active ES2534300T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6T Active ES2534302T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183525.4T Active ES2503740T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10183577.5T Active ES2507544T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Country Status (11)

Country Link
US (25) US8173611B2 (es)
EP (21) EP2298893A1 (es)
JP (11) JP2008519606A (es)
AU (1) AU2005333165B2 (es)
CA (7) CA2857878A1 (es)
DK (1) DK2302055T3 (es)
ES (13) ES2534301T3 (es)
HK (1) HK1204656A1 (es)
PL (1) PL2302055T3 (es)
SI (1) SI2302055T1 (es)
WO (1) WO2006137941A2 (es)

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
CA2572450A1 (en) 2004-05-28 2005-12-15 Ambion, Inc. Methods and compositions involving microrna
WO2006027776A1 (en) * 2004-09-07 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
EP1883709A4 (en) * 2005-04-29 2010-10-13 Univ Rockefeller HUMAN MICRO-RNA AND METHODS OF INHIBITING THEREOF
WO2006133022A2 (en) * 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CN103866017B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
BRPI0619755A2 (pt) 2005-12-12 2011-10-18 Univ North Carolina micrornas que regulam a proliferação e diferenciação de células musculares
ES2545118T3 (es) * 2006-01-05 2015-09-08 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
EP1968622B1 (en) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US7943318B2 (en) * 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2446362T3 (es) * 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
EA015570B1 (ru) 2006-04-03 2011-10-31 Сантарис Фарма А/С Фармацевтическая композиция
US8163708B2 (en) 2006-04-03 2012-04-24 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotide
EP2436785B1 (en) 2006-07-13 2013-09-11 The Ohio State University Research Foundation MIR-29a for diagnosing poor survival prognosis colon adenocarcinoma.
US8304397B2 (en) 2006-08-01 2012-11-06 Board Of Regents, The University Of Texas System Identification of a micro-RNA that activates expression of β-myosin heavy chain
EP2046970B2 (en) † 2006-08-04 2020-04-29 Dublin City University A method of producing recombinant biological products
ES2534430T3 (es) * 2006-08-28 2015-04-22 The University Of Western Australia Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN
US20110021600A1 (en) * 2006-09-04 2011-01-27 Kyowa Hakko Kirin Co., Ltd. Novel nucleic acid
AU2007299748A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
ES2374446T3 (es) 2006-09-19 2012-02-16 The Ohio State University Research Foundation Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181.
EP2086590A4 (en) 2006-10-24 2011-04-06 Univ Leland Stanford Junior MODULATION OF A T-CELL SIGNALING THRESHOLD AND THE SENSITIVITY OF T-CELLS AGAINST ANTIGENE
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
EP2104734A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CN101675165A (zh) * 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标
CA2671296A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
EP2109687B1 (en) 2007-01-31 2014-06-04 The Ohio State University Research Foundation Micro-rna-based methods for the treatment of acute myeloid leukemia
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
WO2008104974A2 (en) * 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
US20100216868A1 (en) * 2007-03-07 2010-08-26 Yissum Research Development Company Of The Hebrew Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
WO2008115387A2 (en) * 2007-03-15 2008-09-25 University Hospitals Of Cleveland Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
EP2136846A4 (en) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd THERAPEUTIC OBJECTIVES AND MOLECULES
US20100273172A1 (en) * 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
EP2142659A4 (en) * 2007-04-30 2010-06-09 Univ Ohio State Res Found METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION
EP1990414A1 (en) * 2007-05-10 2008-11-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means for treating inflammatory diseases, autoimmune diseases and cancer
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
US20090227533A1 (en) * 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
EP2167521A4 (en) 2007-06-15 2011-11-23 Univ Ohio State Res Found ALL-1 ONCOGEN FUSION PROTEINS TO TARGE TREATMENT OF MICRO-RNA REGULATED BY DROSHA
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
EP2808398A1 (en) * 2007-07-31 2014-12-03 The Ohio State University Research Foundation Methods for reverting methylation by targeting DNMT3A and DNMT3B
JP5654347B2 (ja) 2007-07-31 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ミオシンの発現及び筋線維の同一性を制御するマイクロｒｎａ
AU2008283795B2 (en) 2007-07-31 2013-11-21 Board Of Regents, The University Of Texas System A micro-RNA family that modulates fibrosis and uses thereof
US7812003B2 (en) * 2007-08-02 2010-10-12 Safe Stephen H Antisense microRNA and uses therefor
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US20120070442A1 (en) * 2007-08-09 2012-03-22 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for treating cancer
US8716255B2 (en) 2007-08-10 2014-05-06 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
CN101836112A (zh) 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
AU2008296022B2 (en) * 2007-09-06 2014-01-23 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044895A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
JPWO2009044899A1 (ja) * 2007-10-03 2011-02-17 協和発酵キリン株式会社 細胞の増殖を制御する核酸
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009049129A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
CN102137927B (zh) 2007-10-26 2014-03-12 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
CN101980712B (zh) 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
CA2701298A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
JP5654352B2 (ja) * 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
ITRM20070595A1 (it) * 2007-11-15 2009-05-16 Univ Roma Mirna e sirna e loro uso in terapia
US20100240058A1 (en) * 2007-11-23 2010-09-23 Panagene Inc. MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same
JP2011505143A (ja) * 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
KR101325186B1 (ko) 2008-01-23 2013-11-07 (주)바이오니아 이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제
US8580503B2 (en) 2008-01-27 2013-11-12 Rosetta Genomics Ltd. Methods and compositions for diagnosing complications of pregnancy
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
AU2009219193A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
AU2009219190A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2265291B1 (en) 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
WO2009120712A2 (en) 2008-03-24 2009-10-01 New York University Compositions and methods for diagnosing and treating melanoma
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
EP2977468B1 (en) * 2008-03-27 2019-06-19 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
CN102046810B (zh) * 2008-04-07 2014-11-19 康奈尔研究基金公司 血管生成抑制
US20090258928A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US20090280167A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
WO2009137801A2 (en) * 2008-05-08 2009-11-12 The Trustees Of Columbia University In The City Of New York Inhibitory rnas that regulate hematopoietic cells
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2009147658A2 (en) * 2008-06-02 2009-12-10 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
WO2009149318A2 (en) * 2008-06-05 2009-12-10 Research Foundation Of State University Of New York Mirnas as therapeutic targets in cancer
US8247388B2 (en) * 2008-06-06 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Role of miRNA in T cell leukemia
EP2306978A2 (en) * 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of rnai agents
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
US8252534B2 (en) * 2008-06-12 2012-08-28 City Of Hope Micro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders
WO2009153774A2 (en) * 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
US20110077168A1 (en) * 2008-06-17 2011-03-31 Nitzan Rosenfeld Methods for distinguishing between specific types of lung cancers
EP2297357B1 (en) 2008-06-27 2012-10-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Prediction of antiviral therapy response
EP2304030B1 (en) 2008-07-01 2015-11-25 Monsanto Technology LLC Recombinant dna constructs and methods for modulating expression of a target gene
EP2314678B1 (en) * 2008-07-03 2017-02-15 National University Corporation Kobe University Micro-rna associated with rheumatoid arthritis
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
KR101042052B1 (ko) * 2008-08-05 2011-06-16 사회복지법인 삼성생명공익재단 항-ｍｉｃｒｏＲＮＡ를 포함하는 고형암 예방 또는 치료용조성물
WO2010017551A2 (en) * 2008-08-08 2010-02-11 The General Hospital Corporation Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
US8685937B2 (en) 2008-08-09 2014-04-01 University Of Iowa Research Foundation Nucleic acid aptamers
CN102186483A (zh) * 2008-08-11 2011-09-14 德克萨斯大学系统董事会 促进血管完整性的微rna及其用途
AU2009281969A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-RNA-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
WO2010019874A1 (en) * 2008-08-15 2010-02-18 The Translational Genomics Research Institute (Tgen) Methods of predicting the risk of recurrence of cancer
CN102186998A (zh) * 2008-08-19 2011-09-14 人类遗传学与健康缅因州研究院 微小rna和1型神经纤维瘤病在诊断和治疗中
US20120040851A1 (en) 2008-09-19 2012-02-16 Immune Disease Institute, Inc. miRNA TARGETS
US8748101B2 (en) * 2008-11-10 2014-06-10 Battelle Memorial Institute Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010065961A2 (en) 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31
WO2010064248A2 (en) 2008-12-05 2010-06-10 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
EP2208785A1 (en) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
WO2010088668A2 (en) * 2009-02-02 2010-08-05 Cepheid Methods of detecting sepsis
CN102356162A (zh) 2009-02-04 2012-02-15 得克萨斯系统大学董事会 Mir-208和mir-499在治疗心脏病症中的双重靶向
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
US20120027753A1 (en) * 2009-02-26 2012-02-02 The Ohio State University MicroRNAs in Never-Smokers and Related Materials and Methods
US20120029055A1 (en) * 2009-03-19 2012-02-02 Agecy for Science, Technology and Research Modulators of apoptosis and the uses thereof
US20120087992A1 (en) * 2009-03-20 2012-04-12 Jingfang Ju miRNAS AS THERAPEUTIC TARGETS IN CANCER
JP2012522508A (ja) 2009-03-31 2012-09-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロｒｎａ
WO2010120969A1 (en) * 2009-04-15 2010-10-21 Board Of Regents, The University Of Texas System Targeting of the mir-30 family and let-7 family as a treatment for heart disease
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
EP2907879A3 (en) 2009-04-29 2015-10-14 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
WO2010127186A1 (en) 2009-04-30 2010-11-04 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20120264626A1 (en) * 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
US20130177624A1 (en) * 2009-05-08 2013-07-11 David Brian Corry Mirna expression in allergic disease
EP2430579A2 (en) * 2009-05-11 2012-03-21 Koninklijke Philips Electronics N.V. Device and method for comparing molecular signatures
EP2437750A4 (en) * 2009-05-20 2014-11-05 Univ Texas IDENTIFICATION OF MICRO-RNAS INVOLVED IN POSTMYOKARDIAL INFARMETER NEUMODELLATION AND HERBINSUFFICIENCY
US8592388B2 (en) 2009-05-20 2013-11-26 Eth Zurich Targeting MicroRNAs for metabolic disorders
CA2762303A1 (en) * 2009-05-25 2010-12-02 Carola Ponzetto Differentiation therapy for sarcomas
DK2435583T3 (da) * 2009-05-25 2014-09-29 Universit Degli Studi Di Roma La Sapienza miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
US10421961B2 (en) 2009-06-10 2019-09-24 Exostem Biotec Ltd Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
US20100322909A1 (en) 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
WO2011012136A1 (en) * 2009-07-28 2011-02-03 Exiqon A/S A method for classifying a human cell sample as cancerous
FR2948687B1 (fr) * 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
WO2011014697A1 (en) * 2009-07-31 2011-02-03 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
CN102762731B (zh) * 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
US20120214863A1 (en) * 2009-08-05 2012-08-23 The Ohio State University Research Foundation Anti-miR-1 Therapy for Wound Healing
EP2283846A1 (en) * 2009-08-12 2011-02-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. miRNA compounds for treatment of prostate carcinoma
WO2011034811A1 (en) 2009-09-17 2011-03-24 Sigma-Aldrich Co. Short rna mimetics
US20130065949A1 (en) * 2009-10-14 2013-03-14 Baylor College Of Medicine Microrna mirna-31 as a therapeutic approach for the treatment of cancer
WO2011059752A1 (en) * 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Methods and compositions for anti-egfr treatment
EP3118334A1 (en) 2009-11-04 2017-01-18 DiamiR, LLC Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
WO2011063382A1 (en) 2009-11-23 2011-05-26 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
WO2011063456A1 (en) * 2009-11-24 2011-06-03 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
JP5804459B2 (ja) * 2009-12-21 2015-11-04 国立大学法人広島大学 癌疾患用細胞老化促進剤
WO2011084815A1 (en) * 2009-12-21 2011-07-14 Board Of Trustees Of Southern Illinois University Inhibition of ubc9-mediated cancer cell invasion and metastasis
US20120315640A1 (en) 2009-12-21 2012-12-13 Hidetoshi Tahara Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor
US20130012403A1 (en) * 2009-12-23 2013-01-10 George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
WO2011091209A1 (en) * 2010-01-21 2011-07-28 North Carolina State University Small molecule modifiers of microrna mir-122
JP2011188849A (ja) * 2010-02-18 2011-09-29 Okayama Univ 抗腫瘍効果を有するｍｉＲ−７発現プラスミド
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
ES2631458T3 (es) * 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
CA2794522C (en) 2010-04-05 2019-11-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
SI2561078T1 (sl) 2010-04-23 2019-01-31 Cold Spring Harbor Laboratory Nove strukturno oblikovane shRNA
US20140086828A1 (en) * 2010-05-28 2014-03-27 Aaron E. Foster Modified gold nanoparticles for therapy
EP2576785A4 (en) 2010-06-04 2014-12-24 Univ Texas REGULATION OF METABOLISM BY MIR-378
ES2529246T3 (es) * 2010-06-09 2015-02-18 Chanel Parfums Beauté Inhibidores de microARN para usar en la prevención y/o atenuación del envejecimiento cutáneo y/o para hidratar la piel
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012008301A1 (ja) * 2010-07-12 2012-01-19 国立大学法人鳥取大学 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
US8580513B2 (en) * 2010-07-20 2013-11-12 Trustees Of Dartmouth College Methods for determining response to neoadjuvant therapy and survival using MicroRNA-10b
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
US10385314B2 (en) 2010-08-16 2019-08-20 Exostem Biotec Ltd. Methods of generating oligodendrocytes and cell populations comprising same
WO2012023132A1 (en) * 2010-08-16 2012-02-23 Brainstem Biotech Ltd. Methods of generating oligodendrocytes and cell populations comprising same
BR112013003506B1 (pt) 2010-08-17 2022-02-08 Universite De Geneve Método para detectar a presença de uma isoforma de bard1 e método para discriminar câncer
US8642342B2 (en) 2010-08-19 2014-02-04 Regents Of The University Of Michigan Methods for regulating neural differentiation
EP2426217A1 (en) * 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
US9006195B2 (en) * 2010-09-13 2015-04-14 California Institute Of Technology Regulation of hematopoietic stem cell functions through microRNAs
US20130302404A1 (en) * 2010-09-27 2013-11-14 Devrim Gozuacik Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities
EP2622076A1 (en) 2010-09-30 2013-08-07 University of Zürich Treatment of b-cell lymphoma with microrna
WO2012063894A1 (ja) * 2010-11-12 2012-05-18 国立大学法人愛媛大学 マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
AU2011326032B2 (en) * 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
EP2772550B1 (en) 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
WO2012072750A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of colon cancer by analysing mirna expression
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US20140045924A1 (en) * 2010-12-15 2014-02-13 Medimmune, Llc Melanoma treatments
EP2652151A2 (en) 2010-12-15 2013-10-23 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
EP2654801B1 (en) * 2010-12-20 2017-11-01 Agency For Science, Technology And Research Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
BR112013019853A2 (pt) 2011-02-03 2017-03-21 Mirna Therapeutics Inc miméticos sintéticos de mir-34
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
HUE045731T2 (hu) * 2011-02-07 2020-01-28 Gabriella Sozzi Mikro-RNS biomarkerek tüdõtumor diagnosztizálásához és/vagy kockázatának azonosításához
AU2012225506B2 (en) 2011-03-07 2016-11-17 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
ES2855577T3 (es) * 2011-03-30 2021-09-23 Transine Therapeutics Ltd Molécula de ácido nucleico funcional y uso de la misma
WO2012135817A2 (en) * 2011-03-31 2012-10-04 University Of Houston Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
WO2012140234A1 (en) 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
US9556487B2 (en) 2011-04-18 2017-01-31 Diamir, Llc Methods of using miRNA from bodily fluids for early detection and monitoring of mild cognitive impairment (MCI) and alzheimer's disease (AD)
US8765707B2 (en) 2011-04-22 2014-07-01 University Of Houston System MicroRNA-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
EE201100037A (et) * 2011-05-16 2012-12-17 Tartu Ülikool MikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks
MX349048B (es) 2011-06-27 2017-07-07 Galderma Res & Dev Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.
WO2013000870A1 (en) * 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
US8747860B2 (en) * 2011-07-06 2014-06-10 Institute For Systems Biology Methods and compositions to modulate antiviral and immune activity responses
WO2013019259A1 (en) 2011-08-01 2013-02-07 Thomson Licensing Telepresence communications system and method
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US8987224B2 (en) 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
CA2840030A1 (en) 2011-08-12 2013-02-21 Westfaelische Wilhelms-Universitaet Muenster Novel compounds for the treatment of inflammatory bowel disease
WO2013032962A2 (en) * 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
WO2013030362A1 (en) * 2011-08-31 2013-03-07 Universität Zürich Prorektorat Mnw Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US9018188B2 (en) 2011-09-13 2015-04-28 Ottawa Hospital Research Institute MicroRNA inhibitors
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
EP2774989B1 (en) * 2011-11-02 2018-09-05 Osaka City University Double-stranded nucleic acid molecule for gene expression control
JP2015504847A (ja) * 2011-11-30 2015-02-16 シーダーズ−サイナイ メディカル センター 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化
CA2857712A1 (en) * 2011-12-01 2013-06-06 Cincinnati Children's Hospital Medical Center Materials and methods related to nsaid chemoprevention in colorectal cancer
JP2015501645A (ja) * 2011-12-10 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
AU2012352265B2 (en) * 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP6329911B2 (ja) 2012-02-22 2018-05-23 ブレインステム バイオテック リミテッド 星状膠細胞作製のためのミクロｒｎａ
EP2844745A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
CN104160708B (zh) 2012-03-09 2018-12-11 汤姆逊许可公司 同步内容的分布式控制
AR090825A1 (es) 2012-04-25 2014-12-10 Regulus Therapeutics Inc COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
WO2013166240A1 (en) * 2012-05-02 2013-11-07 The Board Of Regents Of The University Of Texas System Micro-rnas involved in macular degeneration
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
JP6126088B2 (ja) 2012-05-26 2017-05-10 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2871239B1 (en) * 2012-07-06 2018-08-29 Takara Bio Inc. Cell capable of producing adeno-associated virus vector
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
JP6340366B2 (ja) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 運動ニューロン疾患を診断および処置する方法
EP2703498B1 (en) * 2012-08-29 2015-01-14 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing
EP2702998A1 (en) 2012-08-31 2014-03-05 IMBA-Institut für Molekulare Biotechnologie GmbH Therapeutic and diagnostic miRNA regulator in kidney disease
US20150344961A1 (en) * 2012-09-11 2015-12-03 New York University Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2014071205A1 (en) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9340787B2 (en) * 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
WO2014099999A1 (en) * 2012-12-18 2014-06-26 Sanford-Burnham Medical Research Institute Methods for improving cardiac contractility
US9994843B2 (en) 2013-02-15 2018-06-12 National University Corporation Tokyo Medical And Dental University Method for assaying microRNA, cancer therapeutic agent, and medicinal composition containing same for cancer therapy
US20160002628A1 (en) * 2013-03-11 2016-01-07 Georgia Tech Research Corporation Methods and compositions for managing vascular conditions
US9006200B2 (en) * 2013-03-13 2015-04-14 Asbestos Diseases Research Foundation MicroRNA-based approach to treating malignant pleural mesothelioma
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2014152243A1 (en) * 2013-03-15 2014-09-25 Albert Einstein College Of Medicine Of Yeshiva University Panel of microrna biomarkers in healthy aging
JP2016519076A (ja) 2013-03-15 2016-06-30 ミルナ セラピューティクス，インク． マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置
EP2968396B1 (en) 2013-03-15 2018-12-19 Miragen Therapeutics, Inc. Locked nucleic acid inhibitor of mir-145 and uses thereof
US9756288B2 (en) 2013-04-10 2017-09-05 Thomson Licensing Tiering and manipulation of peer's heads in a telepresence system
JP2016169158A (ja) * 2013-06-14 2016-09-23 北海道公立大学法人 札幌医科大学 大腸癌を治療および／または診断するための組成物ならびにその利用
GB201310755D0 (en) * 2013-06-17 2013-07-31 Ucl Business Plc Therapy
EP3011691B1 (en) 2013-06-20 2022-11-30 InterDigital CE Patent Holdings System and method to assist synchronization of distributed play out of control
CN105473742A (zh) 2013-06-24 2016-04-06 米尔纳疗法公司 miR-34活性的生物标志物
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9862943B1 (en) * 2013-06-27 2018-01-09 California Institute Of Technology Long noncoding RNAs and cell reprogramming and differentiation
JP6443889B2 (ja) * 2013-08-08 2018-12-26 国立大学法人大阪大学 尿路上皮癌の診断または治療剤
KR101566586B1 (ko) * 2013-08-21 2015-11-16 서울대학교산학협력단 miRNA를 표적으로 하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약학 조성물 및 방법
WO2015044890A2 (en) * 2013-09-26 2015-04-02 Friedrich Miescher Institute For Biomedical Research Tools and methods using mirna 182, 96 and/or 183 for treating pathologies
US20150089870A1 (en) * 2013-10-01 2015-04-02 Wayne State University Population control of invasive plant species and restoration of native plant communities
KR101598070B1 (ko) * 2013-10-17 2016-02-26 한국과학기술연구원 마약 중독 예방 및 치료용 약제학적 조성물
CA2929098A1 (en) 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
CN105917005B (zh) 2013-11-18 2020-09-11 迪阿米尔有限责任公司 使用来自体液的miRNA检测和监控帕金森病(PD)的方法
KR101559131B1 (ko) * 2013-11-18 2015-10-07 한국원자력의학원 ｍｉＲＮＡ를 포함하는 방사선 민감성 증진용 조성물
EP3084008B1 (en) 2013-12-17 2018-07-18 Csir A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
JP6492014B2 (ja) * 2013-12-27 2019-03-27 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
EP3088525A4 (en) * 2013-12-27 2017-08-09 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
JPWO2015133637A1 (ja) * 2014-03-07 2017-04-06 国立大学法人京都大学 マイクロｒｎａ封入ナノ粒子及びその医薬用途
US20160136181A1 (en) 2014-04-01 2016-05-19 Mirna Therapeutics, Inc Microrna dosing regimens
EP3409794B1 (en) * 2014-05-02 2021-03-24 Ruprecht-Karls-Universität Heidelberg Circulating mirnas as early detection marker and prognostic marker
ES2850281T3 (es) * 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
US20170207684A1 (en) * 2014-07-15 2017-07-20 Mitsuba Corporation Brushless wiper motor
LU92499B1 (en) 2014-07-16 2016-01-18 Univ Muenster Wilhelms Mirna 320a as biomarker for inflammatory bowel disease
ES2558262B2 (es) 2014-08-01 2016-07-14 Universidad Católica De Valencia "San Vicente Mártir" Método de diagnóstico de fibromialgia basado en microRNAs
CA2953883A1 (en) 2014-08-07 2016-02-11 Regulus Therapeutics Inc. Targeting micrornas for metabolic disorders
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
MX2017008587A (es) 2014-12-27 2017-10-20 Bonac Corp Mirna natural para controlar la expresion de gen y uso del mismo.
KR20170103841A (ko) 2015-01-20 2017-09-13 미라젠 세러퓨틱스 인코포레이티드 Mir-92 억제제 및 이의 용도
GB201504772D0 (en) 2015-03-20 2015-05-06 Univ Aston Preeclampsia
US20180064748A1 (en) 2015-03-27 2018-03-08 Yeda Research And Development Co. Ltd. Methods of treating motor neuron diseases
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
EP4321627A3 (en) 2015-04-10 2024-04-17 10x Genomics Sweden AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
JPWO2016167366A1 (ja) * 2015-04-17 2018-04-05 国立大学法人 東京大学 眼疾患治療剤
US20180142297A1 (en) * 2015-05-14 2018-05-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing granulomatous diseases
WO2016190899A1 (en) * 2015-05-23 2016-12-01 Beem Alan M H Pri-mirna libraries and methods for making and using pri-mirna libraries
WO2017020009A1 (en) * 2015-07-30 2017-02-02 Regents Of The University Of Minnesota Regulation of mesodermal specification
WO2017027839A1 (en) 2015-08-13 2017-02-16 Somagenics, Inc. Methods and compositions of short small hairpin rnas and micrornas for wound healing
WO2017032776A1 (en) * 2015-08-21 2017-03-02 Universitätsklinikum Jena Human micrornas for treatment of malignant tumours
WO2017057312A1 (ja) * 2015-09-28 2017-04-06 国立大学法人 千葉大学 ｍｉＲ－２００ファミリー阻害により腫瘍を抑制する方法
WO2017058938A1 (en) 2015-09-29 2017-04-06 Research Institute At Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
JP6666002B2 (ja) * 2015-10-07 2020-03-13 国立大学法人京都大学 Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
CA3007744C (en) * 2015-12-10 2022-05-17 Universitat Fur Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
JP6883331B2 (ja) * 2015-12-28 2021-06-09 国立研究開発法人理化学研究所 加齢による生理機能の低下を回復または改善する組成物
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105543225A (zh) * 2016-01-07 2016-05-04 华东师范大学 miR143及其诱导物LTA在制备抑制痤疮炎症药物中的应用
US10771508B2 (en) 2016-01-19 2020-09-08 Nadejda Sarmova Systems and methods for establishing a virtual shared experience for media playback
US11364258B2 (en) 2016-03-04 2022-06-21 Rhode Island Hospital Methods for treating chondrosarcoma using microrna(miR)
WO2017165458A1 (en) 2016-03-21 2017-09-28 Diamir, Llc Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
US11041152B2 (en) * 2016-04-14 2021-06-22 E-Na Biotec Inc. MicroRNA-143 derivative
US11389479B2 (en) 2016-05-02 2022-07-19 University Of Massachusetts T cell differentiation and function regulation by decreasing let7 expression
WO2017210553A1 (en) * 2016-06-03 2017-12-07 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
CN110088278B (zh) * 2016-10-31 2023-08-11 e-NA生物科技公司 双链核酸分子及其用途
AU2017353907B2 (en) 2016-11-01 2023-11-30 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN107058470B (zh) * 2016-11-03 2020-09-01 中国人民解放军陆军军医大学 一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
WO2018191895A1 (zh) 2017-04-19 2018-10-25 深圳市汇顶科技股份有限公司 光强检测方法、装置及智能终端
JP7083818B2 (ja) * 2017-04-28 2022-06-13 一丸ファルコス株式会社 プラセンタ抽出物
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
CN110636853A (zh) * 2017-05-19 2019-12-31 佐治亚州立大学研究基金会公司 重组溶瘤病毒
WO2018231034A2 (ko) * 2017-06-16 2018-12-20 (주)프로스테믹스 암의 예방 또는 치료용 약학적 조성물
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
WO2019116234A1 (en) 2017-12-12 2019-06-20 Nestec S.A. Methods for determining microbiome ribosomal rna composition changes
EP3765619A4 (en) 2018-03-14 2021-12-08 Beth Israel Deaconess Medical Center INHIBITORS OF MICRO-RNA 22
US20210023118A1 (en) * 2018-04-06 2021-01-28 University Of Massachusetts MLK-Regulated microRNAs in Angiogenesis and Tumor Development
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
CN113924127A (zh) * 2019-03-11 2022-01-11 奥克斯纳健康系统公司 在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
US20220251552A1 (en) * 2019-03-25 2022-08-11 The Trustees Of The University Of Pennsylvania Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
CN114885610A (zh) 2019-12-23 2022-08-09 10X基因组学有限公司 使用rna模板化连接进行空间分析的方法
US20210340533A1 (en) * 2019-12-23 2021-11-04 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US20230210883A1 (en) * 2020-03-13 2023-07-06 Duke University Compositions for the treatment of nash and associated disorders and methods of using same
WO2021216708A1 (en) 2020-04-22 2021-10-28 10X Genomics, Inc. Methods for spatial analysis using targeted rna depletion
WO2021237087A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Spatial analysis to detect sequence variants
EP4153775A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
EP4025692A2 (en) 2020-06-02 2022-07-13 10X Genomics, Inc. Nucleic acid library methods
CN116249785A (zh) 2020-06-02 2023-06-09 10X基因组学有限公司 用于抗原-受体的空间转录组学
EP4162074B1 (en) 2020-06-08 2024-04-24 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
EP4165207A1 (en) 2020-06-10 2023-04-19 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
CN112190592B (zh) * 2020-08-25 2022-03-11 苏州市立医院(北区) miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
WO2022076774A2 (en) * 2020-10-08 2022-04-14 The Trustees Of Columbia University In The City Of New York Treatment and detection of liver fibrosis and liver disease using microrna
CN112375823B (zh) * 2020-10-22 2022-09-16 上海交通大学医学院附属瑞金医院 miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2022198068A1 (en) 2021-03-18 2022-09-22 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2022272269A1 (en) * 2021-06-22 2022-12-29 The Curators Of The University Of Missouri Multianalyte biomarkers for lung cancer
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023118546A2 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
KR102583230B1 (ko) * 2023-03-16 2023-09-27 재단법인 전남바이오산업진흥원 뇌경색 예방 또는 치료용 조성물

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007A (en) * 1841-03-16 Improvement in the mode of harvesting grain
US2006A (en) * 1841-03-16 Clamp for crimping leather
US1529202A (en) 1924-07-16 1925-03-10 Joseph H Miller Festooning machine for carrying paper and the like
GB1529202A (en) 1976-02-20 1978-10-18 Ciba Geigy Ag Spectral sensitising dyes
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
JPS55116259A (en) 1979-03-01 1980-09-06 Fuji Photo Film Co Ltd Microimmunoassay method
JPS5745460A (en) 1980-09-02 1982-03-15 Fuji Photo Film Co Ltd Inspection sheet for measuring trace component and inspecting method using said sheet
DE3170135D1 (en) 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement of trace components
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US5011769A (en) * 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US4999290A (en) * 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5708154A (en) 1989-02-24 1998-01-13 City Of Hope RNA-DNA hybrid molecules of nucleic acid
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
GB8920097D0 (en) 1989-09-06 1989-10-18 Ici Plc Amplification processes
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
WO1991006556A1 (en) 1989-10-24 1991-05-16 Gilead Sciences, Inc. 2' modified oligonucleotides
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5486603A (en) * 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5872232A (en) 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5256555A (en) * 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5260191A (en) 1992-01-30 1993-11-09 Agracetus, Inc. Method for diagnosing tumors
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
DE69333073T2 (de) 1992-02-12 2004-04-15 Chromagen, Inc., San Diego Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
DE4204650C1 (es) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
ATE278807T1 (de) 1992-02-19 2004-10-15 New York Health Res Inst Neue anordnungen von oligonukleotiden und ihr nutzen zum sortieren, isolieren, sequenzierung und manipulieren von nukleinsäuren
JP2843675B2 (ja) 1992-03-11 1999-01-06 ダナ−ファーバー・キャンサー・インスチチュート・インコーポレーテッド メッセンジャーｒｎａの同定、単離およびクローニング
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
GB9208545D0 (en) 1992-04-21 1992-06-03 Gatsby Charitable Foundation T Virus resistant plants
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5580726A (en) 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5767259A (en) * 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
US5610287A (en) 1993-12-06 1997-03-11 Molecular Tool, Inc. Method for immobilizing nucleic acid molecules
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
EP1813684A3 (en) 1994-02-14 2009-11-18 Smithkline Beecham Corporation Differently expressed genes in healthy and diseased subjects
DE4406524A1 (de) 1994-02-28 1995-08-31 Boehringer Mannheim Gmbh 3'-RNA-Markierung mit Terminaler Transferase
WO1995025809A1 (en) 1994-03-23 1995-09-28 Ohio University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
US6096314A (en) 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
EP1505159B1 (en) * 1995-03-17 2008-05-28 John Wayne Cancer Institute Detection of breast metastases with a multiple marker assay
US5801155A (en) * 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
DE19518505A1 (de) 1995-05-19 1996-11-21 Max Planck Gesellschaft Verfahren zur Genexpressionsanalyse
WO1996040964A2 (en) 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6418382B2 (en) * 1995-10-24 2002-07-09 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20040142895A1 (en) 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0880598A4 (en) * 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US5837196A (en) 1996-01-26 1998-11-17 The Regents Of The University Of California High density array fabrication and readout method for a fiber optic biosensor
US5670663A (en) 1996-02-14 1997-09-23 Regents Of The University Of California Recovery of taxanes from conifers
US6020481A (en) * 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
CA2252048C (en) 1996-04-12 2008-03-11 The Public Health Research Institute Of The City Of New York, Inc. Detection probes, kits and assays
US5863727A (en) * 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US5739169A (en) * 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
CA2591550C (en) * 1996-06-04 2009-04-28 University Of Utah Research Foundation Monitoring hybridization during pcr
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
AU6451798A (en) 1997-03-07 1998-09-22 Reprogen, Inc. Prostate cancer-specific marker
ID21013A (id) 1997-03-10 1999-04-08 Japan Tobacco Inc Deret nukleotida antipeka
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
NO972006D0 (no) 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
EP1027033B1 (en) 1997-05-14 2009-07-22 The University Of British Columbia High efficiency encapsulation of nucleic acids in lipid vesicles
US6262252B1 (en) 1997-05-19 2001-07-17 Mirus, Inc. Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US6368799B1 (en) 1997-06-13 2002-04-09 Affymetrix, Inc. Method to detect gene polymorphisms and monitor allelic expression employing a probe array
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
AU1366299A (en) * 1997-10-27 1999-05-17 Boston Probes, Inc. Methods, kits and compositions pertaining to pna molecular beacons
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
EP1032705B1 (en) 1997-10-30 2011-12-14 Cold Spring Harbor Laboratory Probe arrays and methods of using probe arrays for distinguishing dna
US5936087A (en) * 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
US6238869B1 (en) * 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6232066B1 (en) * 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6121058A (en) 1998-01-02 2000-09-19 Intel Corporation Method for removing accumulated solder from probe card probing features
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6269846B1 (en) 1998-01-13 2001-08-07 Genetic Microsystems, Inc. Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
US5942398A (en) 1998-02-26 1999-08-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glutx and uses thereof
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
WO1999054459A2 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6037129A (en) * 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
FR2780059B1 (fr) 1998-06-17 2002-10-11 Bio Merieux Procede de marquage d'un acide ribonucleique et fragments d'arn marques ainsi obtenus
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
GB9815799D0 (en) 1998-07-21 1998-09-16 Pharmagene Lab Limited Quantitative analysis of gene expression
US6730477B1 (en) * 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6140054A (en) 1998-09-30 2000-10-31 University Of Utah Research Foundation Multiplex genotyping using fluorescent hybridization probes
AU2144000A (en) 1998-10-27 2000-05-15 Affymetrix, Inc. Complexity management and analysis of genomic dna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9904991D0 (en) * 1999-03-05 1999-04-28 Univ Nottingham Genetic screening
AU777049B2 (en) 1999-03-18 2004-09-30 Qiagen Gmbh Xylo-LNA analogues
US6383752B1 (en) * 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
US6103576A (en) * 1999-04-13 2000-08-15 Microchip Technology Incorporated Dielectric layer of a memory cell having a stacked oxide sidewall and method of fabricating same
DK1178999T3 (da) 1999-05-04 2007-08-06 Santaris Pharma As L-RIBO-LNA-analoger
US6638717B2 (en) 1999-05-19 2003-10-28 Aventis Pharmaceuticals, Inc. Microarray-based subtractive hybridzation
AU5161800A (en) 1999-05-24 2000-12-12 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
US6599912B1 (en) 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
AU4332399A (en) 1999-06-04 2000-12-28 Cheng-Ming Chuong Rna polymerase chain reaction
US6964847B1 (en) 1999-07-14 2005-11-15 Packard Biosciences Company Derivative nucleic acids and uses thereof
US6201112B1 (en) 1999-07-22 2001-03-13 Agilent Technologies Inc. Method for 3′ end-labeling ribonucleic acids
US7005261B1 (en) * 1999-07-29 2006-02-28 British Biocell International Limited Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
US6140500A (en) 1999-09-03 2000-10-31 Pe Corporation Red-emitting [8,9]benzophenoxazine nucleic acid dyes and methods for their use
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US20020094546A1 (en) 1999-10-07 2002-07-18 Shimkets Richard A. Growth factor polypeptides and nucleic acids encoding same
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6528254B1 (en) * 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6191278B1 (en) * 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US6435245B1 (en) 1999-11-18 2002-08-20 Pitney Bowes Inc. System for folding and tabbing sheets
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2001038580A2 (en) 1999-11-26 2001-05-31 Curagen Corporation Nucleic acid probe arrays
US6383749B2 (en) 1999-12-02 2002-05-07 Clontech Laboratories, Inc. Methods of labeling nucleic acids for use in array based hybridization assays
US7205105B2 (en) * 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US6447723B1 (en) 2000-03-13 2002-09-10 Packard Instrument Company, Inc. Microarray spotting instruments incorporating sensors and methods of using sensors for improving performance of microarray spotting instruments
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US20020037540A1 (en) 2000-03-23 2002-03-28 Shujath Ali Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001247782A1 (en) 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
JP2004501613A (ja) 2000-03-27 2004-01-22 ディアデクサス　インコーポレーテッド 乳腺癌の診断、モニタリング、ステージング、イメージング及び処置のための組成物並びに方法
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001251084A1 (en) 2000-03-29 2001-10-08 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
AU2001251223A1 (en) 2000-03-30 2001-10-15 Diadexus, Inc. Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6573048B1 (en) * 2000-04-18 2003-06-03 Naxcor Degradable nucleic acid probes and nucleic acid detection methods
EP1366366B1 (en) 2000-05-10 2010-10-20 Signe BioPharma Inc. Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
JP5078212B2 (ja) 2000-06-02 2012-11-21 ブラッコ・スイス・ソシエテ・アノニム 内皮細胞を標的とするための化合物、それを含む組成物およびその使用方法
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
US20040023230A1 (en) 2000-06-30 2004-02-05 Alexander Olek Method and nucleic acids for pharmacogenomic methylation analysis
US6596490B2 (en) * 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002012563A2 (en) 2000-08-04 2002-02-14 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
JP2002067789A (ja) * 2000-09-05 2002-03-08 Yazaki Corp ランプユニットの電線接続構造
WO2002024718A1 (en) 2000-09-19 2002-03-28 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
US20030082604A1 (en) 2000-09-27 2003-05-01 Swanson Melvin J. High density arrays
US6617112B2 (en) 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts
US7162371B1 (en) 2000-10-11 2007-01-09 Georgia Tech Research Corporation Differentially-expressed conifer cDNAs, and their use in improving somatic embryogenesis
US6350580B1 (en) * 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
US20020150626A1 (en) 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
WO2002048168A1 (en) * 2000-10-24 2002-06-20 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
US7001724B1 (en) * 2000-11-28 2006-02-21 Applera Corporation Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
CN1322143C (zh) 2000-12-04 2007-06-20 普里马根公司 检测线粒体核酸与核基因核酸比率确定药物活性和/或副作用的方法
US20030099976A1 (en) 2001-01-17 2003-05-29 Tai-Jay Chang Androgen receptor complex-associated protein
US20040115671A1 (en) 2001-01-18 2004-06-17 Zlokovic Berislav V Gene expression profiling of endothelium in alzheimer's disease
US7015047B2 (en) * 2001-01-26 2006-03-21 Aviva Biosciences Corporation Microdevices having a preferential axis of magnetization and uses thereof
WO2002064835A2 (en) 2001-01-31 2002-08-22 Ambion, Inc. Methods for nucleic acid fingerprint analysis
US20040110191A1 (en) * 2001-01-31 2004-06-10 Winkler Matthew M. Comparative analysis of nucleic acids using population tagging
US20040058373A1 (en) * 2001-01-31 2004-03-25 Winkler Matthew M. Competitive amplification of fractionated targets from multiple nucleic acid samples
WO2002073504A1 (en) 2001-03-14 2002-09-19 Gene Logic, Inc. A system and method for retrieving and using gene expression data from multiple sources
US20030170623A1 (en) 2001-04-13 2003-09-11 Jingwen Chen Multiplexed gene analysis on a mobile solid support
AU2002307438A1 (en) 2001-04-20 2002-11-05 Ludwig Institute For Cancer Research Cancer-testis antigens
US20050065333A1 (en) 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
CA2445947A1 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
AUPR480901A0 (en) 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2448915A1 (en) 2001-06-01 2002-12-12 Prosanos Corporation Information processing method for disease stratification and assessment of disease progressing
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040086504A1 (en) 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
WO2003001335A2 (en) 2001-06-22 2003-01-03 Gene Logic, Inc. Platform for management and mining of genomic data
WO2003001985A2 (en) 2001-06-28 2003-01-09 Dermtech International Method for detection of melanoma
IL159627A0 (en) 2001-06-29 2004-06-01 Univ Leland Stanford Junior T-cell regulatory genes and diagnostic methods utilizing the same
US20030143571A1 (en) 2001-08-08 2003-07-31 North Carolina State University Infectious disease microarray
AU2002331777A1 (en) 2001-08-30 2003-03-18 Spectral Genomics, Inc. Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
WO2003021227A2 (en) 2001-09-05 2003-03-13 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
AU2002333801B2 (en) 2001-09-06 2008-07-24 Merck Patent Gmbh Genetic analysis of biological samples in arrayed expanded representations of their nucleic acids
EP1425090A2 (en) 2001-09-07 2004-06-09 Corning Incorporated MICROCOLUMN−PLATFORM BASED ARRAY FOR HIGH−THROUGHPUT ANALYSIS
JP4439262B2 (ja) * 2001-09-19 2010-03-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用
US7192586B2 (en) * 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
US6593091B2 (en) * 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
WO2003029459A2 (en) * 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
WO2003029485A2 (en) 2001-10-02 2003-04-10 Azign Bioscience A/S Specific differential display arrays
AU2002367886B8 (en) 2001-10-12 2008-08-14 Perkinelmer Las, Inc. Compilations of nucleic acids and arrays and methods of using them
US20030087298A1 (en) 2001-11-02 2003-05-08 Roland Green Detection of hybridization on oligonucleotide microarray through covalently labeling microarray probe
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
WO2003043487A2 (en) 2001-11-19 2003-05-30 Protometrix, Inc. Method of using a non-antibody protein to detect and measure an analyte
AU2002357368A1 (en) 2001-12-19 2003-07-09 Affymetrix, Inc. Array plates and method for constructing array plates
US7014838B2 (en) * 2001-12-27 2006-03-21 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of brain tumors
US7141372B2 (en) 2002-01-18 2006-11-28 Health Research Incorporated Universal RT-coupled PCR method for the specific amplification of mRNA
WO2003064701A2 (en) 2002-01-30 2003-08-07 Epigenomics Ag Method for the analysis of cytosine methylation patterns
US20030148362A1 (en) 2002-02-07 2003-08-07 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Diagnostic microarray and method of use thereof
AU2003212954A1 (en) 2002-02-08 2003-09-02 Integriderm, Inc. Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
US20060088831A1 (en) 2002-03-07 2006-04-27 University Of Utah Research Foundation Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis
US20070025997A1 (en) 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
EP1495130A4 (en) 2002-04-03 2006-07-05 Agy Therapeutics Inc USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS
DK1504126T3 (da) 2002-05-03 2014-06-10 Univ Duke Fremgangsmåde til regulering af genekspression
DE60323625D1 (de) 2002-05-03 2008-10-30 Vialogy Llc Verfahren zur charakterisierung der ausgangssignale eines microarrays
IL164224A0 (en) 2002-05-20 2005-12-18 Northrop Grumman Corp Point source biological agent detection system
WO2003100012A2 (en) 2002-05-24 2003-12-04 Nimblegen Systems, Inc. Microarrays and method for running hybridization reaction for multiple samples on a single microarray
AUPS261402A0 (en) 2002-05-28 2002-06-20 Compusign Pty Ltd Array monitoring
US20030228579A1 (en) 2002-06-05 2003-12-11 Uri Alon Ordering genes by analysis of expression kinetics
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
US20040029128A1 (en) 2002-08-08 2004-02-12 Epigenomics, Inc. Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
US20040029121A1 (en) 2002-08-08 2004-02-12 Susan Cottrell Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
AU2003268105B2 (en) 2002-08-16 2011-11-03 John Wayne Cancer Institute Molecular lymphatic mapping of sentinel lymph nodes
AU2003270654A1 (en) 2002-09-12 2004-04-30 Baylor College Of Medecine System and method for image segmentation
AU2003267583A1 (en) 2002-09-19 2004-04-08 The Chancellor, Master And Scholars Of The University Of Oxford Molecular arrays and single molecule detection
EP1556402B1 (en) * 2002-09-25 2011-06-22 University of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003291287A1 (en) 2002-11-01 2004-06-07 John Fonda Crary Apkc isoforms in nervous system disorders and cancer
EP1418241A1 (en) 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
JP4939055B2 (ja) 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ 癌の診断および治療のための組成物および方法
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004046324A2 (en) 2002-11-15 2004-06-03 University Of Massachusetts Allele-targeted rna interference
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
JPWO2004050125A1 (ja) 2002-12-03 2006-03-30 株式会社高研 腫瘍細胞の増殖及び／又は浸潤の抑制剤
JP4230457B2 (ja) * 2002-12-18 2009-02-25 サード・ウェーブ・テクノロジーズ・インク 低分子核酸の検出方法
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
CN101061236A (zh) 2003-01-13 2007-10-24 艾默瑞大学 在正常细胞和癌细胞中检测基因表达的方法
DE602004012531T2 (de) 2003-01-16 2009-04-16 North Carolina State University Verarmung an endogenen primordialen keimzellen in vogelspezies
WO2004066183A2 (en) * 2003-01-22 2004-08-05 European Molecular Biology Laboratory Microrna
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
EP1592791A2 (en) 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040224337A1 (en) 2003-03-04 2004-11-11 Erik Foehr Use of biomolecular targets in the treatment and visualization of tumors
EP1604022A2 (en) * 2003-03-06 2005-12-14 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
WO2004090108A2 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
US20050112604A1 (en) 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
WO2004090105A2 (en) * 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20040229211A1 (en) 2003-05-13 2004-11-18 Yeung Wah Hin Alex Sensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory syndrome (SARS)
WO2004105573A2 (en) 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ES2864206T3 (es) 2003-06-02 2021-10-13 Univ Massachusetts Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US20060183128A1 (en) 2003-08-12 2006-08-17 Epigenomics Ag Methods and compositions for differentiating tissues for cell types using epigenetic markers
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
EP1682662A1 (en) 2003-11-10 2006-07-26 Noxxon Pharma AG Nucleic acids specifically binding bioactive ghrelin
US20050130172A1 (en) 2003-12-16 2005-06-16 Bayer Corporation Identification and verification of methylation marker sequences
US20050130170A1 (en) 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
KR100522307B1 (ko) * 2004-02-19 2005-10-19 변영철 화장용브러시
US7402389B2 (en) 2004-02-24 2008-07-22 The Translational Genomics Research Institute (Tgen) Compositions and methods for prognosis of cancers
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
JP2007530679A (ja) * 2004-03-27 2007-11-01 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 癌治療のための組成物および方法
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP1745150A4 (en) * 2004-04-20 2008-02-27 Genaco Biomedial Products Inc METHOD FOR DETECTING NCRNA
EP1747023B2 (en) 2004-05-04 2016-03-09 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for reducing hcv viral genome amounts in a target cell
AU2005243410B2 (en) * 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
WO2005116261A2 (en) 2004-05-24 2005-12-08 Albert Einstein College Of Medecine Of Yeshiva University Rna expression microarrays
CA2572450A1 (en) 2004-05-28 2005-12-15 Ambion, Inc. Methods and compositions involving microrna
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20050287539A1 (en) 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
CA2574088C (en) 2004-07-21 2013-09-17 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
AU2005272816B2 (en) 2004-08-10 2011-08-11 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
US7893034B2 (en) 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
US20060057595A1 (en) 2004-09-16 2006-03-16 Applera Corporation Compositions, methods, and kits for identifying and quantitating small RNA molecules
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20090186353A1 (en) 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US20060078894A1 (en) * 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
US20060134661A1 (en) 2004-10-12 2006-06-22 Richard Essner Treatment of cancer and compositions
FR2877350B1 (fr) * 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
US7074622B2 (en) * 2004-11-15 2006-07-11 Eastman Kodak Company Method and system for sorting and separating particles
WO2006060653A2 (en) 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20060154275A1 (en) 2004-12-02 2006-07-13 The Board Of Trustees Of The Leland Stanford Junior University Regulated genes in cervical cancer
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2006069584A2 (en) * 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
WO2006113679A2 (en) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
KR101379364B1 (ko) * 2005-02-08 2014-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 ｍｄａ-7을 포함하는 조성물
US7495073B2 (en) * 2005-03-24 2009-02-24 Asia Hepato Gene Company Short isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
US20090062184A1 (en) 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
GB2425311A (en) * 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
CA2607256A1 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070072201A1 (en) * 2005-05-16 2007-03-29 Kohne David E Method for producing improved nucleic acid oligomer functional homogeneity and functional characteristic information and results and oligomer application results
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
GB0601102D0 (en) * 2006-01-19 2006-03-01 Nuclea Biomarkers Llc Kinase Peptides And Antibodies
US20070054287A1 (en) * 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2006128245A1 (en) 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
CA2611507A1 (en) * 2005-06-09 2006-12-21 Epoch Biosciences, Inc. Improved primer-based amplification methods
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
KR101140575B1 (ko) * 2005-06-30 2012-05-02 엘지디스플레이 주식회사 액정표시장치 검사공정
CN103866017B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
CN101365440A (zh) 2005-11-04 2009-02-11 默克公司 用saha、卡铂和紫杉醇治疗癌症的方法以及其他联合治疗
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US20100286044A1 (en) 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
EP1968622B1 (en) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2545118T3 (es) 2006-01-05 2015-09-08 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
WO2007087451A2 (en) 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2522749A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
CA2655355C (en) * 2006-06-16 2014-05-06 Taisho Pharmaceutical Co., Ltd. Use of rpn2 gene expression inhibitor
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2436785B1 (en) 2006-07-13 2013-09-11 The Ohio State University Research Foundation MIR-29a for diagnosing poor survival prognosis colon adenocarcinoma.
US8466117B2 (en) 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
AU2007299804A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
AU2007299748A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
EP2104734A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
CN101675165A (zh) 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标
CA2671294A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en) 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
US8389486B2 (en) 2007-01-26 2013-03-05 Rosetta Genomics, Ltd Methods for treating hematopoietic malignancies
WO2008095096A2 (en) 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
KR101540296B1 (ko) 2007-04-20 2015-07-31 시그마-타우 레어 디지즈 리미티드 효소적 항암 요법
EP2142659A4 (en) 2007-04-30 2010-06-09 Univ Ohio State Res Found METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION
WO2008137867A2 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising mir34 therapeutic agents for treating cancer
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en) 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US7993831B2 (en) 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
CN101980712B (zh) 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2009086156A2 (en) 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
AU2009219193A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof
EP2268832A2 (en) 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2271757A2 (en) 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
US20090258928A1 (en) 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
EP2306978A2 (en) 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of rnai agents
US20100090959A1 (en) 2008-10-14 2010-04-15 Sony Ericsson Mobile Communications Ab Forming a keyboard from a combination of keys displayed on a touch sensitive display and on a separate keypad
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010084488A1 (en) * 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
US7665785B1 (en) 2009-04-08 2010-02-23 Newton Paul A Column pipe catch tool
WO2011050129A1 (en) * 2009-10-21 2011-04-28 Trustees Of Dartmouth College Microrna-10 antagonists and microrna-10 targets for use in the treatment of a glioma
WO2011059752A1 (en) 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Methods and compositions for anti-egfr treatment
WO2011063382A1 (en) 2009-11-23 2011-05-26 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
WO2011063456A1 (en) 2009-11-24 2011-06-03 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
EP2622076A1 (en) 2010-09-30 2013-08-07 University of Zürich Treatment of b-cell lymphoma with microrna
BR112013019853A2 (pt) * 2011-02-03 2017-03-21 Mirna Therapeutics Inc miméticos sintéticos de mir-34
CN105969773A (zh) * 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
US8785709B2 (en) 2011-03-30 2014-07-22 University Of Louisville Research Foundation, Inc. Catalytic isomerisation of linear olefinic hydrocarbons
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
JP2015501645A (ja) 2011-12-10 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
JP2016519076A (ja) 2013-03-15 2016-06-30 ミルナ セラピューティクス，インク． マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置
CN105473742A (zh) 2013-06-24 2016-04-06 米尔纳疗法公司 miR-34活性的生物标志物
US20160136181A1 (en) 2014-04-01 2016-05-19 Mirna Therapeutics, Inc Microrna dosing regimens

Also Published As

Publication number Publication date
US20150344883A1 (en) 2015-12-03
ES2503765T3 (es) 2014-10-07
US9447414B2 (en) 2016-09-20
EP2808390A1 (en) 2014-12-03
EP2292755A1 (en) 2011-03-09
US20080176766A1 (en) 2008-07-24
SI2302055T1 (sl) 2015-01-30
JP2014217386A (ja) 2014-11-20
EP2281889A1 (en) 2011-02-09
JP2014217385A (ja) 2014-11-20
JP5620556B2 (ja) 2014-11-05
ES2503743T3 (es) 2014-10-07
US20150284719A1 (en) 2015-10-08
EP2302052A1 (en) 2011-03-30
CA2857878A1 (en) 2006-12-28
EP2302051B1 (en) 2015-01-07
EP2281889B1 (en) 2014-07-30
ES2534303T3 (es) 2015-04-21
EP2302056A1 (en) 2011-03-30
US20150005366A1 (en) 2015-01-01
JP2014217387A (ja) 2014-11-20
ES2534302T3 (es) 2015-04-21
AU2005333165A1 (en) 2006-12-28
US20150344881A1 (en) 2015-12-03
EP2298894A1 (en) 2011-03-23
ES2503738T3 (es) 2014-10-07
ES2503739T3 (es) 2014-10-07
US20150004221A1 (en) 2015-01-01
CA2857881A1 (en) 2006-12-28
JP5389690B2 (ja) 2014-01-15
US20150275213A1 (en) 2015-10-01
US20130303591A1 (en) 2013-11-14
DK2302055T3 (da) 2014-10-13
US8173611B2 (en) 2012-05-08
HK1204656A1 (en) 2015-11-27
EP2314688B1 (en) 2014-07-16
EP2302054B1 (en) 2014-07-16
EP2302054A1 (en) 2011-03-30
US20170037404A1 (en) 2017-02-09
EP2281886A1 (en) 2011-02-09
EP2302055A1 (en) 2011-03-30
JP2014223080A (ja) 2014-12-04
US9068219B2 (en) 2015-06-30
JP2010178741A (ja) 2010-08-19
CA2587189A1 (en) 2006-12-28
EP2322616A1 (en) 2011-05-18
US8563708B2 (en) 2013-10-22
US20150284720A1 (en) 2015-10-08
EP2287303A1 (en) 2011-02-23
US20150361431A1 (en) 2015-12-17
ES2534301T3 (es) 2015-04-21
US9506061B2 (en) 2016-11-29
US8765709B2 (en) 2014-07-01
EP2302051A1 (en) 2011-03-30
EP2284265A1 (en) 2011-02-16
US20140348908A1 (en) 2014-11-27
JP2016165292A (ja) 2016-09-15
ES2503741T3 (es) 2014-10-07
AU2005333165B2 (en) 2012-07-19
ES2503740T3 (es) 2014-10-07
US20140314833A1 (en) 2014-10-23
JP2014012020A (ja) 2014-01-23
CA2857879A1 (en) 2006-12-28
JP2008519606A (ja) 2008-06-12
EP2302055B1 (en) 2014-08-27
US20120065248A1 (en) 2012-03-15
WO2006137941A3 (en) 2008-01-03
US8946177B2 (en) 2015-02-03
EP2284265B1 (en) 2015-01-07
EP2292756B1 (en) 2014-07-16
EP2292756A1 (en) 2011-03-09
EP2302053A1 (en) 2011-03-30
US20150352046A1 (en) 2015-12-10
EP2281888A1 (en) 2011-02-09
US7960359B2 (en) 2011-06-14
EP2302052B1 (en) 2015-01-07
WO2006137941A9 (en) 2007-03-08
EP2281887A1 (en) 2011-02-09
US20080050744A1 (en) 2008-02-28
US20110313025A1 (en) 2011-12-22
EP2808389A1 (en) 2014-12-03
US20140031415A1 (en) 2014-01-30
US20150342981A1 (en) 2015-12-03
US20090176723A1 (en) 2009-07-09
EP2281888B1 (en) 2015-01-07
US20080171715A1 (en) 2008-07-17
ES2534304T3 (es) 2015-04-21
WO2006137941A2 (en) 2006-12-28
EP2314688A1 (en) 2011-04-27
JP5596085B2 (ja) 2014-09-24
ES2534300T3 (es) 2015-04-21
ES2507544T3 (es) 2014-10-15
EP1838852A2 (en) 2007-10-03
US9051571B2 (en) 2015-06-09
US20150299705A1 (en) 2015-10-22
JP2014217381A (ja) 2014-11-20
PL2302055T3 (pl) 2015-02-27
US20140350086A1 (en) 2014-11-27
EP2298893A1 (en) 2011-03-23
US20130143945A1 (en) 2013-06-06
CA2850323A1 (en) 2006-12-28
CA2857901A1 (en) 2006-12-28
EP2302056B1 (en) 2015-01-07
JP2014217384A (ja) 2014-11-20
US8058250B2 (en) 2011-11-15
JP2012228254A (ja) 2012-11-22
EP2281886B1 (en) 2014-07-16
EP2298894B1 (en) 2014-07-16
EP2287303B1 (en) 2014-07-02
CA2857880A1 (en) 2006-12-28
US9382537B2 (en) 2016-07-05
US20140348907A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
ES2503742T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US9284554B2 (en) Micro-RNA scaffolds and non-naturally occurring micro-RNAs
CN102573856B (zh) 用于制备微小rna 的方法及其治疗性应用
JP2010539959A5 (es)
US11041201B2 (en) Methods for detection of RNase activity
US20110151430A1 (en) VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
CN103476947A (zh) 寡聚体的增强的生物分布
JP2020536554A5 (es)
US8859239B2 (en) Methods for small RNA sequencing
Efimenko et al. Data supporting that miR-92a suppresses angiogenic activity of adipose-derived mesenchymal stromal cells by down-regulating hepatocyte growth factor
NM_205822 et al. Supplementary Table
Omnibus AUC: area under curve. KEGG: Kyoto Encyclopedia of Genes and Genomes. GEO: Gene
Name_ID SUPPLEMENTARY TABLE
LUAD 17 hsa-mir-222 88.23 Table S1: List of miRNAs returned from at least one run of the DE algorithm. The list is sorted according to decreasing number of times it has been reported. The value of the k-esim row refears to the classification accuracy obtained using the subset of the first k miRNAs.